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Healthcare Spending and Utilization of Lung Cancer Patients 
Using 2002-2012 Health Insurance Claims Data 
 
Background: Over the past decades, lung cancer has one of the highest fatality rates, 
and is the leading cause of cancer-related mortality and disease burden not only in 
South Korea but also worldwide. Studies focused on lung cancer are well documented, 
however, the factors that are associated with survival probability of lung cancer 
patients and their healthcare spending and utilization using long periods of large 
dataset is less researched in this country. The purpose of this study was to investigate 
how different individual and hospital factors are associated with total, inpatient, 
outpatient spending and utilizations measured by length of stays and outpatient days 
among nationwide dead or 5 years follow-up lung cancer patients using 2002-2012 
health insurance claims data. 
  
Materials and Methods: We used nationwide lung cancer patients’ health insurance 
claims during 2002-2012 which accounted for 1,417,380 (673,122 inpatients and 
744,258 outpatients). We transposed the dataset into a retrospective cohort design 
study that the unit of analysis is information of each lung cancer patient. We included 
patients who newly diagnosed with lung cancer after 2005 and dead or follow-up of 
60 months which eventually included patients diagnosed during 2005-2007. 
Furthermore, this study also excluded patients who had inpatient spending less than 
KRW 400,000 to minimize bias of real lung cancer patient selection. We then 
calculated various spending and utilization measures (total, inpatient, outpatient 
spending, length of stays and outpatient days). Survival time was also measure for 
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each patient that the variable is measured by time from diagnosis to all-cause 
mortality or end of 60 months follow-up. Finally we obtained total population for 
analysis of 53,451 lung cancer patients and matched 916 hospitals. Hospital data 
included characteristics of the hospital, such as hospital type, teaching status, number 
of beds, specialists, and nurses. Cox-proportional hazard model was performed to 
investigate survival probability of lung cancer patients by using individual factors. In 
order to investigate individual and hospital factors associated with healthcare 
spending and utilization of lung cancer patients, multi-level linear mixed models that 
avoid problems created by possible nesting of patient level observations within 
hospital clusters and overestimation of significance were performed. 
 
Results: Our retrospective cohort design study using nationwide claim data of past 
decade showed that increase in new lung cancer cases during year 2005 to 2007 
(16,654 in 2005, 18,149 in 2006, 18,648 in 2007 which are similar to actual number 
of patients reported by national cancer center), increased spending and utilization 
(total spending of KRW 22,883,645 to KRW 27,462,222; inpatient LOS of 51.4 days 
to 58.8 days; outpatient utilization of 25.4 days to 26.1 days for patient diagnosed in 
2005 and 2007 respectively), and higher proportion of spending and utilization during 
very first periods after diagnosis and last periods before death or follow-up ends of 
lung cancer patients (about 70% over total), no significant improvements of 5 years 
survival rates by year of diagnosis (20.4%, 19.7%, and 20.3% for diagnosed in 2005, 
2006, and 2007 respectively, P=0.462) and higher spending and utilization trend 
among dead population (5-years survivors: total spending of KRW 24,486,381, 
inpatient LOS of 39.2 days, outpatient utilization of 40.9 days; Dead population: total 
spending of KRW 15,936,865~54,945,330, inpatient LOS of 44.4~107.8 days, 
Outpatient utilization of 9.0~66.0 days). Results of Cox-proportional hazard model 
showed that indifferent hazard ratio by insurance type (health insurance vs. medical 
aids, HR=0.99, P=0.489), however, hazard ratio was increased for male (female 
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HR=0.74, P<0.001), as older age of diagnosis after 40+ for lung cancer (HR range 
from 2.02 to 6.63, P<0.001). Using the multi-level linear mixed analysis models, we 
found evidences of differences in the use of healthcare resources among individual 
and hospital factors that individual with health insurance (2.9% higher in total 
spending, P<0.001; 23.8% higher in outpatient days, P<0.001), male (5.6% higher in 
total spending, P<0.001; 8.6% higher in outpatient days, P<0.001), 40-79 age group 
(28.0% to 61.0% higher in total spending, P<0.001; 24.8% to 34.0% in LOS, P<0.001; 
38.9% to 65.8% higher in outpatient days, P<0.001) and hospital type with 
tertiary/large (27.6%, 12.7% higher in total spending), teaching (35.6% higher in total 
spending, P<0.001; 13.4% higher in LOS, P=0.001; 21.9% higher in outpatient days, 
P<0.001) had relatively higher spending and utilization among nationwide 5 year 
follow-up lung cancer patients. Some population groups showed that higher hazard 
ratios with higher healthcare spending and utilization. 
 
Discussion & Conclusion: This study might suggest that efficient manner of 
healthcare policy implementation for patients’ spending and utilization in order to 
maintain financial viability of national health insurance program that the allocation of 
limited health-care resources demands an agreed rational allocation principle, and 
consequently priority setting is considerably importance. In addition, healthcare 
spending and utilization considered to be targeted to under-served population groups 
that will ensure efficient locus of healthcare service delivery by accounting for 
survival probability of different sub-population groups. Results of this study might be 
useful to health policy makers not only in South Korea but also international readers 
that need to develop a national cancer management strategy that reduce differences in 
the use of healthcare resources and flexible healthcare benefits plan which might 
helpful to targeted sub population groups. 
 





1. Study Background 
 
Over the past decades, cancer has been the leading cause of death and is associated 
with the largest disease burden in Korea.1 Of all cancers, lung cancer has one of the 
highest fatality rates, and is the leading cause of cancer-related mortality in South 
Korea2 and worldwide.3 World Health Organization reported that 1.8 million new 
lung cancer cases were estimated in 2012 (12.9% of the total cases of cancer), in the 
latest GLOBOCAN 2012.4 
In Korea, the latest statistics show that the numbers of incident lung cancer cases 
were 21,753 (out of total 218,017 cancer cases; 69.7% male) and prevalent lung 
cancer cases were 48,795 (out of total 1,097,253 cancer prevalence; 65.3% male) in 
2011.5 In 2013, 75,334 cancer deaths were reported, with lung cancer accounting for 
22.8% of all deaths (17,177, 72.8% male) the highest cancer death in both males and 
females in Korea.5 Five-year survival rates for lung cancer are about 20% during 
2007-2011,5 one of the lowest survival rates, because most patients had advanced-
stage lung cancer at their initial diagnosis.6  
Economic burden of cancer has increased over the decades because healthcare in 
general and cancer care in particular are very expensive.7 Moreover, diagnostic 
advancement of new cancer care and cancer treatments cause costs that contribute to 
rising economic burdens for cancer care.8 Increased costs are outpacing the inflation 
rates and budgetary level of each nation, hence questions were raised regarding the 
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cost-benefit of proven interventions by both individuals and society levels.8 Ideally, 
more effective and less toxic care and treatments should be initiated, but these 
innovations require further costs.9 Ideas of healthcare care costs or expenditure should 
be utilized efficient manner considering survival probability, severity of illness, and 
others in order to reduce useless resource usage had been continuously discussed 
throughout the world for a long period of time. 
Healthcare utilization is associated with time close to dying, suggesting that a large 
proportion of expenditures occur in the last few months prior to death.10-12 In the 
United States, healthcare spending in the last year of life consumes approximately 27% 
to 30% of the Medicare budget and has done so consistently over the past 
decades.12,13 Most of these costs were the result of life-sustaining care, with a 
significant portion of costs accrued from acute care in the final 30 days of life.13 
Healthcare utilization is also associated with cost trend of cancer patients after their 
diagnosis, using SEER (Surveillance, Epidemiology, and End Results)-Medicare 
combined dataset, were ―U-shaped,‖ with high costs near the times of diagnosis and 
death, and lower costs in between.14 Although several research had investigated the 
spending and utilization of late stage cancer, not many of studies conducted in this 
country. 
Healthcare spending and utilization might be influenced by health insurance type or 
various health policy initiatives. The Korean government introduced mandatory social 
health insurance for employees of large corporations in 1977 and achieved universal 
health insurance program in 1989.15 Since health insurance program in South Korea is 
controlled exclusively by the government under a single-payer system,16 even with 
the universal coverage through the mandatory National Health Insurance (NHI), only 
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54.5% of total health expenditures are associated with the public sector, comparing to 
72.3% for OECD countries as of 2012.17 Korea also faces with health care spending 
issue that the highest rate of growth, more than twice the OECD average.17 Total 
health expenditures in South Korea accounted for 7.6% of GDP in 2012. It ranks 27th 
among the 34 OECD (Organization for Economic Co-operation and Development) 
countries that percentage of total health expenditure is lower than the OECD average 
of 9.3%, however, the increase in its health expenditure rate is 9.3%, which is higher 
than that of most OECD countries.17 
However, NHI members still need to pay high out-of-pocket payment (copayments) 
and full payment for uncovered services, to some extent related to fee-for-service 
reimbursement system that might supplier induces demand and relatively fast 
adoption of state-of-art technologies.16 Since cancer is associated with expensive 
treatments, drugs, and other diagnostic procedures, NHI initiated various copayment 
policies over a decade to alleviate patients’ financial burden. In January 2004, NHI 
initiated a copayment policy that limits copayments to 20% for cancer patients in 
outpatient services where normal copay is 50%. In September 2005, the coverage was 
expanded to 10% copayments for both inpatient and outpatient services for cancer 
patients. In December 2009, the coverage was expanded again to 5% copayments for 
both inpatient and outpatient services.18 Recently, coverage for four major serious 
disease including cancer has been more expanded; however, there are no mechanisms 
of controlling rising healthcare expenditure among those patients groups. 
In order to investigate patients’ healthcare spending and utilization mechanism 
associated with health insurance coverage, the landmark RAND health insurance 
experiment conducted in the late 1970s randomized families to different health 
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insurance plans that varied in their cost-sharing. They found that families subjected to 
higher cost-sharing reduced the use of health services virtually across the board, 
including fewer physician visits and fewer adult inpatient hospital stays, less 
preventive and non-preventive care, and less use of both effective and non-effective 
care.19,20 There are similar findings in a pediatric population.21 The study results 
might suggest that unplanned coverage expansion would cause unplanned healthcare 
spending utilization increase. 
As the population of patients with lung cancer increases, the expenditure on lung 
cancer treatments is a huge economic burden.22 Only few studies have been 
conducted in Korea that investigated socio-economic costs of cancer treatment. A 
study conducted in 2008 by Kim et al., from the National Cancer Control Research 
Institute, they estimated the economic burden of all cancer in Korea in 2002 at $9.4 
billion which accounted for 1.72% of the gross domestic product (GDP) and lung 
cancer accounted for $1.3 billion23 which is huge burden for entire country. Recently, 
Park et al. found evidences that the economic burden of cancer in Korea showed a 
rapid rise from USD 11,424 million in year 2000 to USD 20,858 million in year 2010 
which accounted an average annual growth rate of 8.9%.24 Although economic burden 
of lung cancer has drastically increased, Korea achieved universal NHI program 
decades ago, it is roughly 10 years since the various cancer related insurance policies, 
and 10-year plan for cancer patient control (Figure 1) have been implemented, 
however, there has been no comprehensive investigation into nationwide healthcare 
spending and utilization and its associated factors for lung cancer patients yet.  
In addition, the studies on lung cancer epidemiology are well-documented, but the 
factors that associated with survival time of lung cancer patients and their healthcare 
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spending and utilization using long periods of large dataset is also less researched in 
this country. In addition to investigation of patients’ healthcare spending and 
utilization, association with hospital factors is also very important as 70% of deaths 
occur at hospitals in Korea.25 Although patients with advanced cancer prefer to 
receive care and die at home,26,27 most patients die in hospitals.26-31 
 
 




The structure and availability of healthcare resources appear to influence place of 
death more than the actual preference of patients and families.33,34 Furthermore, South 
Korea is ranked second highest in average hospital length of stay followed by Japan 
and the highest in outpatient visits among OECD countries17 which provide important 
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research rationale for investigating hospital level factors of healthcare spending and 
utilization.  
The main purpose of this study is to investigate and hypothesize various individual 
and hospital level factors that influence healthcare spending and utilization and its 
relation to translated health outcomes measured by survival probability of lung cancer 
patients. We believe the research findings will prove useful to health policy makers 
that the allocation of limited health-care resources demands an agreed rational 
allocation principle, and consequently priority setting is of considerable importance,35 
especially those residing in countries with national health insurance programs based 
on fee-for-service payments, and others concerning cancer management policy. The 





2. Study Objectives  
  
The purpose of this study is to investigate how different individual and hospital 
factors are associated with total, inpatient, outpatient spending and utilizations 
measured by length of stays, outpatient days among nationwide 5 years follow-up of 
lung cancer patients using 2002-2012 health insurance claims data. 
 
The detailed objectives of this study were as follows: 
 
(1) To analyze how different types of patient factors including age group strata, 
sex, types of insurance, duration of diagnosis to death etc. affected total, 
inpatient, outpatient spending and utilizations measured by length of stays 
and outpatient days among nationwide 5 years follow-up lung cancer patients 
using 2002-2012 health insurance claims data. 
(2) To analyze how different types of hospital factors including type of hospital, 
teaching status, and other structural factors affected total, inpatient, outpatient 
spending and utilizations measured by length of stays and outpatient days 
among nationwide 5 years follow-up lung cancer patients using 2002-2012 
health insurance claims data. 
(3) To analyze how different types of patient factors including age group strata, 
sex, types of insurance etc. affected survival probability of nationwide 5 





II. Literature Review 
 
1. Factors associated with spending and utilization for lung cancer patients 
 
Previous research found evidences that treatment intervention with surgery, 
chemotherapy, or radiotherapy has been shown to improve lung cancer survival.36 In 
addition, the recent literature contains numerous reports of factors affecting the 
diagnosis, treatment and outcomes of lung cancer across a growing list of population 
subgroups, including race and ethnicity, sex, income, and place of residence etc.  
Regarding the issue of spending and utilization with lung cancer patients, 
international research primarily focused on racial or ethnicity factors on lung cancer 
utilization. A study conducted by Bach et al., using the Surveillance, Epidemiology, 
and End Results (SEER) data between 1985 and 1993 in United States, found 
evidences of utilization differences that the lower rate of surgery found in black 
patients by 12.7 percentage than for white patients (64.0 percent vs. 76.7 percent, 
P<0.0 01).37 Lathan et al. also examined racial differences of lung cancer treatment 
and found evidences that rate of surgery for black patients is lower than whites 
patients among lung cancer patients, even after access to care has been demonstrated. 
Further, the black patients are more likely to refuse surgery and not to have surgery 
recommended by the way.38 However, other studies found that nonwhites also tended 
to have higher treatment costs than whites, although they had significantly shorter 
survivals.39 
In addition to racial/ethnic differences, age was also played a role for factors 
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influencing lung cancer utilization. Using the data of the Virginia Cancer Registry 
(VCR), 1985-89, Smith et al. found the evidences that increasing age was associated 
with lower likelihood of receiving therapy (OR=0.35), thoracotomy (OR=0.27), and 
more use of radiation therapy compared to surgery (OR=1.69) when they matched the 
VCR with claims from Medicare Part A and B, census tract data and the Area 
Resource File.40 Using the population-based random sample of newly diagnosed lung 
cancer patients, diagnosed within 10 separate geographic areas, Potosky et al. 
concluded that the use of recommended therapy was significantly inversely associated 
with age, further, stage-specific analyses revealed a significant decline in the use of 
recommended surgery with increasing age at diagnosis for early-stage lung cancer.41  
Furthermore, lower education were associated with less likelihood of receiving 
treatment (OR=0.78), or radiation instead of surgery (OR=1.22) and patients in urban 
areas were less likely to receive therapy (OR=0.67).40 Large variations exist in the use 
of therapies according to age, race or ethnicity, and marital status in another study.41 
 Access for healthcare utilization is very significant issue in lung cancer patient. 
People within lower socio-economic status, especially lower income status, more 
likely person experiences a broad spectrum of problems and being poor will not only 
diminish access to medical care and treatment but also have poorer housing, less 
social support, and a risk-promoting lifestyle, with a greater likelihood of smoking.42 
Black race, probably acting as a proxy for lower socioeconomic status, was 
associated with both a less likely seeing a cancer specialist and subsequently 
receiving chemotherapy. After seeing such a physician, treatment decisions seem to 
be mostly explained by appropriate medical factors, however, racial and 
socioeconomic differences still exist at both steps.43 
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Insurance status also played a significant role for factors influencing healthcare 
utilization of lung cancer patients’ treatment and patients with lung cancer who do not 
have insurance have been shown to have more limited access to care, since insurance 
coverage is an important determinant of access to care and is one potential cause of 
differences in lung cancer care outcomes. Silverstein et al. found evidences that 
residence in an area with a high proportion of Medicaid recipients was a predictor of 
advanced stage in esophageal cancer patients; further, decreased utilization of health 
services was evident among older, poor, black, rural cancer patients.44 
A systematic review also showed that examined the association between insurance 
status and lung cancer practices and outcomes concluded that comparing with patients 
with private or Medicare insurance, patients with Medicaid or no insurance had 
poorer lung cancer outcomes, including higher incidence rates, later stage at diagnosis, 
and poorer survival.45 Their conclusion was that some of the differences may be 
secondary to residual confounding from smoking and other health behaviors, but 
available data suggest that patients with lung cancer without insurance do poorly 
because access to care is limited and/or they present with more advanced disease that 
is less amenable to treatment.45 In the domestic research, the authors also found 
evidences that individuals with private health insurance spent larger inpatient costs 
than those without, but no differences were found in utilization in other service such 
as hospital admissions, hospital days and physician visits.46 Sex differences in the 
development and treatment of lung cancer is another very critical issue. The Society 
for Women's Health Research hosted a thought leaders’ roundtable to review issues 
and advances related to sex differences and presented recent data on the 
epidemiological aspects of lung cancer in women, lung tumor biology, and emerging 
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trends in clinical research in 2006.47 In other study, women tended to have higher 
treatment costs than men; they also had more favorable survivals using linked SEER-
Medicare data were used to construct cost profiles by service type and treatment 
phase for roughly 80,000 incident lung cancer cases in patients aged 45 to 85 years at 
diagnosis.39 Recently research done by Forrest et al., the study concluded that 
socioeconomic inequalities in lung cancer treatment using systematic review and 
meta-analysis method.48 Specifically, the study showed that patients with lung cancer 
living in more socioeconomically deprived circumstances are less likely to receive 
any type of treatment, surgery, and chemotherapy, further, these inequalities cannot be 
accounted for by socioeconomic differences in stage at presentation or by differences 
in health care system by analyzing forty-six papers which met inclusion criteria.48 
In contrast to previous research, some studies concluded that socio-economic 
positions are not related to lung cancer utilization. The study conducted in England, 
using population-based cohort identified in the Thames Cancer Registry in which 
15,582 lung cancer patients diagnosed between 2006 and 2008 included, found 
evidences that the likelihood of being diagnosed as having early-stage disease did not 
vary by socioeconomic quintiles and differences which could not fully be explained 
by social differences in stage at diagnosis, co-morbidity and treatment.49 In other 
study conducted in New Zealand also concluded that socio economic position was not 
associated with receipt of any treatments using the data analysis of the New Zealand 
Cancer Registry.50 International research found evidences primarily that the 
differences exist among different groups of population. Not only in this country but 




Although patient level factors associated with healthcare spending and utilization of 
patients were well researched, hospital level factors were less researched. Only few 
studies examined that hospital characteristic especially for teaching status and 
hospital type associated with higher spending and utilization. Teaching hospitals were 
historically commanded high payment rates more than its counterparts in order to 
support their cost structure because of their reputations for providing high-quality 
healthcare, their specialized health service capacity, and education of medical 
students.52,53 In addition, large hospitals may include a greater share of physicians, 
nurses, allied health professionals and other ancillary costs.54 
 
2. Factors associated with survival probability for lung cancer patients 
 
Lung cancer epidemiology study showed that survival differs internationally. In the 
UK, fewer than 10% of lung cancer patients diagnosed survive more than 5 years, 
although higher survival rates found in Nordic countries, the USA, Australia, and 
Canada.55,56 The international range in conditional 5-year survival seems to have 
widened.56 Lung cancer has become the number one killer among cancers worldwide. 
Although lung cancer remains the leading cause of cancer-related mortality in the 
United States, its incidence is decreasing. In 2008, 215,020 new cases were expected 
and 161,840 persons were projected to die from the disease in the United States. 
Non–small cell lung cancer accounts for most lung cancer and carries a 5-year 
survival rate of 15%.57 
 Strong evidence for socio-economic differences in cancer survival and mortality 
was revealed few decades ago by a comprehensive review in the late 1990s, for many 
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cancers and in many populations.58 These variations were resilient to the variety of 
ways in which socio-economic status had been determined. Possible reasons for 
survival differences between social groups were also reviewed.59 Stage at diagnosis 
was the factor most often cited, but its influence varied by anatomic site and between 
populations, and it was not the sole explanatory factor for socio-economic differences 
in survival in much of the research. In the research the authors also concluded that 
further study into the causes of socio-economic differences in survival was required, 
particularly in relation to treatment differentials and psychosocial factors.59 
The racial factor is seen primarily in men and is significantly greater in younger age 
groups. Gadgeel et al. concluded that a significant racial difference in survival rates 
has developed over the past 30 years and suggested possible reasons for racial 
differences due to smoking habits, socioeconomic variables, and the metabolism of 
tobacco carcinogens although higher lung cancer incidence rates in blacks remains 
unclear.60 Many other studies have focused on socioeconomic status of African 
Americans as the sole cause of these differences. Other studies, however, have 
identified additional factors related to risks for poor outcomes in blacks with lung 
cancer.61 Socioeconomic inequalities in incidence of, and survival from, the majority 
of cancers also have been reported.62 A recent nonsystematic review revealed 
socioeconomic inequalities in receipt of treatment for colorectal cancer,63 and it has 
been suggested that socioeconomic differences in access to treatment might at least 
partially explain socioeconomic differences in survival.64 Although incidence of lung 
cancer is higher and survival poorer in the most deprived patient groups,62 unintended 
variations in outcome that result from the way that health interventions are organized 
and delivered have been described as intervention-generated inequalities.65 
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Recently, survival improved for most cancers, but inequalities in survival were still 
wide for many cancers in 2006 (Only the deprivation gap in 1-year survival narrowed 
slightly over time). A majority of the socioeconomic differences in survival occurred 
soon after a cancer diagnosis, regardless of the cancer prognosis.62 Using the SEER 
data between 1985 and 1993 in United States, Bach et al. found evidence five-year 
survival rate was also lower for blacks (26.4 percent vs. 34.1 percent, P<0.001).37 
Another study found evidences that 5-year conditional survival rates increase for all 
ethnicities as time from diagnosis increases, but African Americans continued to have 
lower conditional survival rates compared with other ethnic groups, even up to 5 
years from diagnosis.66  
Insurance status also played a role that possible reasons for uninsured and Medicaid 
insured cancer patients’ poorer survival compared with privately insured cancer 
patients, even after adjustment for other factors.45 Suggested reasons may include that 
―poorer health with more comorbidity and unhealthy behaviors, no or inadequate 
preventive health care and management of chronic conditions prior to cancer 
diagnosis, barriers to receiving treatment and adhering to a treatment regimen such as 
high cost, inability to navigate the health care system, misinformation about and 
mistrust of the health care system, lack of a usual source of health care, lack of 
transportation, lack of time off from work, no treatment or delay in receiving 
treatment, not all providers accept uninsured or Medicaid insured patients, and lower 
quality treatment by providers primarily serving the uninsured and Medicaid insured.‖ 
45,67-70  Sex differences in lung cancer survival also presented by analysis based on 
nationwide population-based sample, which concluded that elderly women with early 
lung cancer had better risk-adjusted survival regardless of the type of treatment. 
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Hence, sex differences were observed among untreated patients suggests that lung 
cancer in women may have a different natural history.71 Age is another major 
determinant of cancer risk and it is know that the peak of incidence was noted in the 
cohort of patients aged 60–69 years.72 The recent study conducted by Riihimäki et al. 
presented that significant impact of age at diagnosis on the survival of 17,431 lung 
cancer patients in which concluded deceasing survivals among lung cancer patients of 
nationwide Swedish Cancer Registry who diagnosed 2002–2010.73 Although patient 
level factors associated with survival probability of patients were well researched, 
hospital level associations were not researched yet.  
Previous literatures are conceptualized in the figure 2 that various individual and 
hospital level factors are associated with not only healthcare spending and utilization 
but also survival probability of lung cancer patients by using mainly each country’s 
large sized cohort dataset.  
 
Figure 2. Conceptual Framework of factors associated with healthcare spending and 
utilization, survival probability of lung cancer patients. 




















III. Material and Methods 
 
1. Study Population and Design 
 
We collected the nationwide lung cancer inpatient and outpatient claims data 
between 2002 and 2012 to investigate healthcare spending, utilizations, and its 
associations with individual and hospital level factors. Lung cancer patients were 
defined by ICD-10 (International Classification of Diseases-10) codes of C33-C34. 
This dataset contained health insurance claim details including inpatient, outpatient 
spending covered by NHI, length of stay, outpatient days, admission and discharge 
date, outpatient utilization date, date of death (all-cause mortality), age, sex, days in 
the Intensive Care Unit (ICU), days on a ventilator during hospitalization, and 
hospitals where patients utilized healthcare resources. 
Total numbers of nationwide lung cancer patients’ health insurance claims during 
2002-2012 were 1,417,380 which included 673,122 inpatients and 744,258 
outpatients. Then we matched the patients’ claims data with hospital characteristics 
data by hospital ID number. Hospital level data contained hospital id, hospital type 
(tertiary, large, small), teaching status (resident teaching hospital vs. non-teaching 
hospital), and other structural factors including number of beds, number of nurses, 
number of specialists. After the matching, we transposed the dataset to a retrospective 
cohort design with the baseline as diagnosis of each patient.  
In order to measure follow-up duration and initial diagnosis time of each patient, we 
calculated those time variables using the dataset. Using all the previous claims, we 
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identified each year’s new lung cancer cases. For example, we searched all claim 
records of 2002-2004 in order to detect new lung cancer cases in year 2005. If a 
patient had no record in 2002-2004, then we assumed the patient was newly 
diagnosed in 2005. Likewise we searched all claim records of 2002-2005 in order to 
detect new lung cancer cases in year 2006. If a patient had no record in 2002-2005, 
then we assumed the patient was newly diagnosed in 2006. 
We excluded patients diagnosed during year 2002-2004 in order to ensure the newly 
diagnosed lung cancer cases. The assumption behind this method is that patients will 
utilize healthcare resources at least once in 3 years after lung cancer diagnosis. Then 
we also excluded patient diagnosed with lung cancer during 2008-2012, in order to 
include only patient who followed-up until 60 months. We also excluded patients who 
spent less than KRW 400,000 assuming that lung cancer patients at least admitted to 
hospital and spent certain amount for inpatient healthcare resources. Finally, we 
obtained total population for analysis of 53,451 lung cancer patients who newly 
diagnosed lung cancer during year 2005 to 2007 and matched 916 hospitals after we 
excluded missing individual and hospital variables. The figure 3 shows flow chart 
how total populations for analysis were obtained. 
We also calculated total, inpatient, outpatient spending and utilization related to their 
followed up periods, specific periods of time after diagnosis (example. 3 months 
before follow-up ends, 6 months before follow-up ends, and 12 months before follow-
up ends), specific periods of time before death or end of follow up (example: 3 
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- Inpatient spending less than KRW 400,000 
   
Total Population for Analysis  
- 53,451 Patients 
: Diagnosed during 2005-2007 and follow-up of 60 months or death 
- 916 Hospitals 
 
Figure 3. Flow Chart of Subject Selection 
 
Using the conceptual framework of study design (Figure 4), we ought to find factors 
associated with spending and utilization of nationwide lung cancer patients.  
As noted, there’s only few studies have examined and evaluated healthcare spending 
and utilization for nationwide lung cancer patients and their survival probability in 





Figure 4. Conceptual Framework of study design 
 
2. Patient and Hospital Level Variables 
 
In order to investigate spending and utilization of nationwide lung cancer patients, 
we aggregated claims associated with spending and utilization from each patient’s 
diagnosis of lung cancer. We also calculated survival or follow-up times of each lung 
cancer patient using the date of death and end of follow-up date (2012.12.31). 
Dependent variables were basically divided into two sections that spending and 









- Total spending during follow-up periods 
- Inpatient spending during follow-up periods 
- Outpatient spending during follow-up periods 
Utilization 
- Inpatient LOS during follow-up periods 
- Outpatient Days during follow-up periods 
 
Inpatient and outpatient healthcare spending is the sum of Fee-For-Services (FFS) 
claims for each patient’s hospitalization and outpatient visit. South Korea established 
a national health insurance (NHI) program in 1989; all types of hospital generally use 
a fee-for-service (FFS) reimbursement system. Patients have considerable freedom to 
choose and access care providers; no restrictions on the use of primary, secondary, 
and tertiary medical institutions and there are no penalties for repeated care.74,75 
In Korea, the fee for services (FFS) catalogue is negotiated by the government, 
providers, and other stakeholders every year. We discounted all inpatient and 
outpatient spending to 2012 levels using each year’s negotiated FFS catalogue. The 
yearly mean of the foreign exchange (FX) rate was 1USD = 1126.88 KRW in year 
2012. Furthermore, we also converted spending information in order to have realistic 
numbers. In Korea, coverage for cancer patients have been different by years (table 2), 
we estimated total spending which include covered spending from claim data and 
non-covered spending from estimation. Dependent variable as specific periods of 
time after diagnosis (ex. 3 months before follow-up ends, 6 months before follow-up 
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ends, and 12 months before follow-up ends), specific periods of time before death or 
end of follow-up (ex. 3 months after diagnosis, 6 months after diagnosis, and 12 
months after diagnosis) is also assessed but included in the appendix. 
 
Table 2. NHI coverage for cancer patients (both inpatient, outpatients) after 2005 
Year Inpatient Outpatient 
2005 63.0 75.9 
2006 69.7 73.9 
2007 70.1 75.7 
2008 70.8 71.6 
2009 63.9 79.8 
After 2010 69.0 75.1 
Source: Statistics Korea. 2013 
 
The dataset also contained patient level health insurance claim details including 
admission date, outpatient visit date, age group, sex, insurance type, Intensive Care 
Unit (ICU) days and days on ventilator during hospitalization, status of respiratory 
disability, and usage of home-oxygen therapy. Lists of patient level variables are 
contained in table 3. Age variable grouped into eight categories in order to see 
specific age effect on healthcare spending and utilizations. Type of insurance is a 
proxy measure of socio-economic-status (SES) in Korea, we used as the variable as 
patient’s SES in this study. ICU days and ventilator days were also aggregated into 
specific period of time like as dependent variable were calculated. This study also 
included diagnosed year of lung cancer for each patient. In order to adjust severity of 
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patients, we also included a variable, death after diagnosis, that present specific 
survival time of each dead lung cancer patients or 5 years survivors. 
 





(1) ≤19 (2) 20–29 (3) 30–39 (4) 40–49 
(5) 50–59 (6) 60–69 (7) 70–79 (8) 80≤ 
Sex (1) Men (2) Women 
Type of Insurance (1) National Health Insurance (2) Medical Aid 
Duration of Diagnosis to  
Death or F/U end 
(1) Within a year (2) During 1-1.99yrs (3) During 2-2.99yrs 
(4) During 3-3.99yrs (5) During 4-4.99yrs (6) 5yrs survivors 
Diagnosed Year (1) 2005 (2) 2006 (3) 2007 
Home Oxygen Therapy (1) User (2) Non-User 
Respiratory Disability (1) Disabled (2) Non-Disabled 
ICU days Total number of days using ICU 
Ventilator days Total number of days using ventilators 
 
Hospital-level data included characteristics of the hospital, such as hospital type 
(tertiary, large, small), teaching status (teaching and non-teaching), number of beds, 
number of specialist physicians, number of nurses. Lists of hospital variables are 
included in the table 4. We used hospitals data where patients were lastly admitted to.  
According to the Korean Hospital Association (KHA), Korean hospitals are 
categorized as tertiary university research hospitals, mid-sized general hospitals, or 
small-sized general hospitals based on the number of beds and medical departments. 
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Tertiary university research hospitals contain more than 1000 beds and almost all 
possible medical departments, and mid-sized general hospitals typically contain more 
than 300 beds and nine major medical departments or more than 100 beds and seven 
major medical departments. Hospitals with fewer than 100 beds or a shortage of 
medical departments are classified as small general hospitals.76 We categorized 
hospital type into those three groups based on the criteria (tertiary hospital, large 
hospital, small hospital). Teaching status defined as whether hospitals have resident 
training programs.  
 




(1) Tertiary Hospital (2) Large hospital 
(3) Small hospital 
Teaching status (1) Teaching (2) Non-Teaching 
Number of beds Total number of general ward’s beds 
Number of nurses Total number of registered nurses 





3. Statistical Analysis 
 
We first examined number of newly diagnosed 5 years follow-up lung cancer 
patients and their characteristics. In order to investigate characteristics of nationwide 
lung cancer patients, descriptive statistics were generated; means and standard 
deviations were calculated for continuous variables, and frequencies and relative 
percentages were calculated for categorical variables. Means of survival time or 
follow-up periods for survivors by patient’s characteristics were also examined. Bi-
variate analyses were conducted to see group difference for example, age group, sex, 
duration of diagnosis to death, diagnosed year, insurance type, usage of home-oxygen 
therapy, and respiratory disability rating etc. We also investigated various spending 
and utilization measures including 1) Spending and utilization by characteristics of 
patients, 2) Spending and utilization by patients’ time stages of lung cancer patients, 
and 3) Spending and utilization by periods before death and after diagnosis of lung 
cancer patients.  
We then examined the crude association between each patient characteristic and 
survival probability of lung cancer patients by using Kaplan–Meier curves. To 
investigate the associations of all patient characteristics and spending with survival 
probability of lung cancer patients, Cox proportional hazard models were used to 
calculate hazard ratios and the corresponding 95% confidence intervals. In this study, 
a P-value less than 0.05 (two-tailed) were considered statistically significant.  
We used multi-level mixed models by employing SAS’s ―Proc Mixed‖ procedure 
and random intercept effects that accounted for hierarchical data structure. The unit of 
analysis is each patient who is nested within a hospital and the model analyze the 
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patient-, hospital- level characteristics together. We used the model in order to avoid 
problems created by possible nesting of patient level observations within clusters 
(hospitals) and overestimation of significance. We adjusted patient- and hospital-level 
confounders in order to investigate individual and hospital factors that influence 
spending and utilization of nationwide lung cancer patients. We first examined total, 
inpatient, outpatient spending then also investigated association with utilization 
measured by inpatient days (hospital length of stay) and outpatient days. Both random 
intercept and maximum-likelihood option were also employed to run the models.  
Additionally, we conducted multi-level mixed models by taking specific period 
before dead or end of follow-up and specific periods after diagnosis as dependent 
variables which were included in Appendix C and D. All of dependent variables were 
skewed because the data include spending and utilization information, we took the 
natural log for each dependent variable. Distribution of each dependent variable and it 
natural log distribution is presented in Appendix B. 
SAS 9.3 (SAS Institute, Cary, NC) was used for all calculations and analyses. All 
statistical tests were two-tailed, and we rejected null hypotheses of no difference if p-
values were less than .05, or, equivalently, if the 95% CIs of risk point estimates 
excluded 1. 
 
4. Ethics Statement 
 
This study was approved by an institutional review board of Graduate school of 






1. Characteristics of Patients and Hospitals 
 
The results of descriptive analysis of nationwide 5 years follow-up lung cancer 
patients and hospitals where the patients were admitted to were included in this 
section. The numbers of newly diagnosed lung cancer cases during 2005-2007 in 
Korea were presented in table 5. During the year 2005 to 2007, 53,364 of new lung 
cancer patients were diagnosed with lung cancer by national cancer center (NCC). 
Similarly, this study identified 53,451 cases (differences of 81 patients comparing to 
NCC report) using the methodology used to identify lung cancer patients in this study 
using nationwide health insurance claims data. 
 
Table 5. Comparison of new lung cancer cases during 2005-2007 in Korea. 
  Year 
Total 
  2005 2006 2007 
Reported by National Cancer Center 17,229 17,725 18,410 53,364 
In this Study 16,654 18,149 18,648 53,451 
 
Characteristics of 5 years follow-up lung cancer patients diagnosed during 2005-
2007 in Korea showed in table 6. Total numbers of patients were 53,451. Age of 
diagnosis with lung cancer was highest in 70-79 (32.8%), followed by 60-69 (32.2%), 
50-59 (15.4%). Age 80+ was accounted 11.7% which is fourth raked in number of 
new lung cancer cases among different age group strata. Male were 38,046 which 
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accounted for 71.2% of total patients. Among 53,451 patients, 48,586 had national 
health insurance program (90.9%) and 15,405 enrolled in medical aids program 
(9.1%). About 52% of patients were dead with a year of lung cancer diagnosis, 68% 
of them were dead within 2 years of diagnosis. 5 years survivors were accounted for 
20.1%. Numbers of lung cancer patients were slightly increased during 2005 to 2007. 
Small numbers of patients were received respiratory disability grading (0.8%), and 
home-oxygen therapy (2.1%). Means and standard deviation of episode spending and 
utilization were also presented in table 6.  
Mean total spending was KRW 25,451,471 which composed of inpatient spending 
of KRW 18,338,230 and outpatient spending of KRW 7,113,241. Mean episode ICU 
days were 1.7 days and ventilator days were 1.2 days. Nationwide lung cancer 
patients utilized average 56.0 days of inpatient services and 25.9 days of outpatient 
days in their 5 years of follow-up.  
Table 6 shows that follow-up time of lung cancer patients by different types of 
characteristics who diagnosed lung cancer during 2005-2007 in Korea. Mean follow-
up time of lung cancer death was 21.7 months. Older patients had relatively shorter 
follow-up time than younger groups. The trend is gradually increased as getting 
younger. Patients who had health insurance (22.0 months Vs. 18.8 months of medical 
aids), female (25.5 months Vs. 20.1 months of male), having disability status (27.0 
months Vs. 21.7 months of non-disabled), using home-oxygen therapy (26.2 months 
Vs. 21.6 months of non-users) were longer in their follow-up time. Patient’s follow-
up time by diagnosed year of lung cancer was quite similar (21.9 months in 2005, 
21.5 months in 2006, and 21.7 months in 2007). 
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Table 6. Characteristics of 5 years follow-up lung cancer patients who diagnosed 
during 2005-2007  
     N/Mean %/SD 
Total              53,451  100 
Age Group       
  80-              6,259  11.7 
  70-79            17,543  32.8 
  60-69            17,219  32.2 
  50-59              8,206  15.4 
  40-49              3,300  6.2 
  30-39                 738  1.4 
  20-29                 137  0.3 
  -19                   49  0.1 
Sex       
  Male            38,046  71.2 
  Female            15,405  28.8 
Insurance Type     
  Health Insurance            48,586  90.9 
  Medical Aids              4,865  9.1 
Home-Oxygen Therapy     
  User              1,138  2.1 
  Non-User            52,313  97.9 
Respiratory Disability     
  Disabled                 414  0.8 
  Non-disabled            53,037  99.2 
Death After Diagnosis     
  Within a year            27,692  51.8 
  During 1-1.99 years              8,360  15.6 
  During 2-2.99 years              3,562  6.7 
  During 3-3.99 years              1,873  3.5 
  During 4-4.99 years              1,208  2.3 
  5 yrs Survivors            10,756  20.1 
Diagnosed Year       
  2005            16,654  31.2 
  2006            18,149  34.0 
  2007            18,648  34.9 
        
ICU Days*                    1.7                   7.3  
Ventilator Days*                  1.2                   6.7  
Total Spending*     25,451,471      27,124,232  
Inpatient Spending*     18,338,230      19,716,931  
Outpatient Spending*       7,113,241      13,468,481  
Inpatient LOS*                56.0                 71.0  
Outpatient Days*                25.9                 34.7  
* Mean/SD       
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Table 7. Follow-up time of lung cancer patients who diagnosed during 2005-2007 
by difference of characteristics.  
     Mean  SD 
Total   21.7 22.4  
Age Group       
  80-                11.4                 16.9  
  70-79                16.8                 20.1  
  60-69                23.8                 22.7  
  50-59                29.6                 23.5  
  40-49                32.7                 23.5  
  30-39                32.9                 23.6  
  20-29                36.5                 24.3  
  -19                43.3                 23.6  
Sex       
  Male                20.1                 21.6  
  Female                25.5                 23.8  
Insurance Type       
  Health Insurance                22.0                 22.5  
  Medical Aids                18.8                 21.5  
Home-Oxygen Therapy     
  User                26.2                 19.5  
  Non-User                21.6                 22.4  
Respiratory Disability     
  Disabled                27.0                 22.4  
  Non-disabled                21.7                 22.4  
Death After Diagnosis     
  Within a year                  4.5                   3.3  
  During 1-1.99 years                17.0                   3.4  
  During 2-2.99 years                29.2                   3.4  
  During 3-3.99 years                41.5                   3.4  
  During 4-4.99 years                53.8                   3.5  
  5 yrs Survivors                60.0                      -  
Diagnosed Year       
  2005                21.9                 22.4  
  2006                21.5                 22.3  
  2007                21.7                 22.5  
 
Table 8 depicts characteristics of hospitals where 5 years follow-up lung cancer 
patients diagnosed during 2005-2007 were admitted to in Korea. Number of beds 
was around 350 beds and number of nurses was 111.1. Average specialist 
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physicians were 38.9. Most of hospitals were non-teaching hospitals (N=774, 
84.5%) and tertiary hospitals, large hospitals, and small hospitals accounted for 
4.8%, 31.1%, 64.1%, respectively. 
 
Table 8. Characteristics of hospitals where 5 year follow-up lung cancer patients 
diagnosed during 2005-2007 were admitted to  
     Mean/N  SD/% 
# of Beds          351.5        319.9  
# of Nurses          111.1        193.9  
# of Specialist physician            38.9          77.5  
Teaching Status*     
  Teaching 142 15.5 
  Non-Teaching 774 84.5 
Hospital Type*     
  Tertiary 44 4.8 
  Large  285 31.1 
  Small 587 64.1 
* N/%       
 
Table 9 presents characteristics of 5 years follow-up lung cancer patients by 
duration of diagnosis to death. More of older patients were dead within a year of 
diagnosis of lung cancer. Male population was dead more within a year of 
diagnosis of lung cancer (54.5% of male vs. 45.2% of female) and their 5 year 
survival rate was lower than female (17.8% vs. 25.8%).  Health insurance 
holders had lower mortality within a year of lung cancer diagnosis (51.1%), and 
their 5 years survival rate was also higher than medical aids holders (20.5% vs. 
16.1%). 5 years survival rate of lung cancer patient who diagnosed during 2005 to 
2007 was not significantly different in this study (about 20 months, P=0.463). 
Home oxygen therapy usage and respiratory disability grade also had different 5 
year survival rates (P<0.001). 
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Table 9. Characteristics of 5 years follow-up lung cancer patients by duration of diagnosis to death or follow-up end 
  Total 
Duration of diagnosis to death or follow-up end 
P Within a year 1-1.99 years 2-2.99 years 3-3.99 years 4-4.99 years 5 yrs Survivors 
N % N % N % N % N % N % 
Age Group 
              
  80- 6,259 4,643 74.2 662 10.6 287 4.6 146 2.3 99 1.6 422 6.7 <.0001 
  70-79 17,543 10,863 61.9 2,533 14.4 1,020 5.8 504 2.9 343 2.0 2,280 13.0 
 
  60-69 17,219 8,067 46.8 2,976 17.3 1,206 7.0 613 3.6 457 2.7 3,900 22.6 
 
  50-59 8,206 2,896 35.3 1,462 17.8 677 8.3 390 4.8 193 2.4 2,588 31.5 
 
  40-49 3,300 970 29.4 562 17.0 300 9.1 176 5.3 103 3.1 1,189 36.0 
 
  30-39 738 210 28.5 136 18.4 64 8.7 35 4.7 13 1.8 280 37.9 
 
  20-29 137 34 24.8 24 17.5 7 5.1 6 4.4 - - 66 48.2 
 
  -19 49 9 18.4 5 10.2 1 2.0 3 6.1 - - 31 63.3 
 
Sex   
              
  Male 38,046 20,722 54.5 6,227 16.4 2,399 6.3 1,172 3.1 752 2.0 6,774 17.8 <.0001 
  Female 15,405 6,970 45.2 2,133 13.8 1,163 7.5 701 4.6 456 3.0 3,982 25.8 
 
Insurance Type 
              
  Health Insurance 48,586 24,839 51.1 7,695 15.8 3,256 6.7 1,734 3.6 1,088 2.2 9,974 20.5 <.0001 
  Medical Aids 4,865 2,853 58.6 665 13.7 306 6.3 139 2.9 120 2.5 782 16.1 
 
Home-Oxygen Therapy 
             
  User 1,138 358 31.5 261 22.9 189 16.6 102 9.0 83 7.3 145 12.7 <.0001 
  Non-User 52,313 27,334 52.3 8,099 15.5 3,373 6.4 1,771 3.4 1,125 2.2 10,611 20.3 
 
Respiratory Disability 
              
  Disabled 414 157 37.9 73 17.6 44 10.6 25 6.0 27 6.5 88 21.3 <.0001 
  Non-disabled 53,037 27,535 51.9 8,287 15.6 3,518 6.6 1,848 3.5 1,181 2.2 10,668 20.1 
 
Diagnosed Year   
              
  2005 16,654 8,543 51.3 2,627 15.8 1,123 6.7 582 3.5 382 2.3 3,397 20.4 0.463 
  2006 18,149 9,409 51.8 2,871 15.8 1,249 6.9 635 3.5 413 2.3 3,572 19.7 
 





2. Healthcare spending and utilization of lung cancer patients 
 
As noted in table 6, mean total spending was KRW 25,451,471 which composed 
of inpatient spending of KRW 18,338,230 and outpatient spending of KRW 
7,113,241. In addition, nationwide lung cancer patients utilized average 56.0 days 
of inpatient services and 25.9 days of outpatient days in their 5 years of follow-up 
Table 6).  
 
1) Spending and utilization by characteristics of patients 
 
Table 10 presents total, inpatient, outpatient spending and inpatient, outpatient 
utilization by various patient characteristics. All spending and utilization were 
higher in age groups of 40-59. For example total spending of age group 40-49 was 
KRW 40,256,515 which was a lot higher than mean total spending (KRW 
25,451,471). Inpatient spending (KRW 26,563,430), outpatient spending (KRW    
13,693,085), inpatient LOS (72.8 days), and outpatient days (40.0 days) were also 
higher than mean spending and utilization. 
Sex differences were also identified that male had more spending on total and 
inpatient but somewhat lower for outpatient spending. Inpatient LOS was longer 
for female. People who hold health insurance had higher total, inpatient, and 
outpatient spending (KRW 26,261,248, KRW 18,749,721, and KRW 7,511,527 
respectively). Outpatient spending was especially two times higher than people 
who hold medical aids (KRW 7,511,527 for health insurance vs. KRW 3,135,620 
for medical aides). Home Oxygen Therapy users and respiratory disabled 
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population had higher spending and utilization as well. 
Lung cancer patients who diagnosed in 2007 had higher total spending (KRW 
27,462,222), inpatient spending (KRW 19,670,472), outpatient spending (KRW 
7,791,750), inpatient LOS (58.8 days), and outpatient days (26.1 days) than 
diagnosed year of 2005 and 2006. Lung cancer patient who died during 3-3.99 
years after diagnosis had highest in spending and utilization which accounted for 
total spending of KRW 56,994,155, inpatient spending of KRW 34,431,861, 
outpatient spending of KRW 22,562,295, inpatient LOS of 107.8 days, and 
outpatient days of 66.0 days which accounted a lot higher than mean spending and 
utilization. 5 years survivors had relatively lower spending than mean spending 
and utilization which accounted for total spending of KRW 24,486,381, inpatient 
spending of KRW 14,727,775, outpatient spending of KRW 9,758,606, inpatient 
LOS of 39.2 days, and outpatient days of 40.9 days. Mean spending and 
utilization for patients who died within a year of diagnosis had somewhat lower 
spending and utilization which accounted for total spending of KRW 15,936,865, 
inpatient spending of KRW 13,855,150, outpatient spending of KRW 2,081,715, 
inpatient LOS of 44.4 days, and outpatient days of 9.0 days. 
The results showed that patient who died during 1-5 years after diagnosis of lung 
cancer had much higher spending and utilization than mean spending and 
utilization, although 5 years survivors were relatively similar to the mean. This is 
because we have more than half of patient who died within a year after diagnosis 
of lung cancer and their spending and utilization is relatively lower than other 




Table 10. Spending and utilization by characteristics of nationwide 5 year follow-up lung cancer patient diagnosed during 2005-2007 
  
Total Spending Inpatient Spending Outpatient Spending Inpatient LOS Outpatient Days 
  
Mean SD Mean SD Mean SD Mean SD Mean SD 
Age Group 
           
 
80- 8,829,025 10,462,344 7,750,721 9,040,450 1,078,303 3,371,445 38.3 62.7 7.1 15.0 
 
70-79 18,280,309 19,729,220 14,234,546 15,317,140 4,045,763 8,801,127 49.2 62.3 17.7 26.8 
 
60-69 29,304,826 25,951,356 20,927,218 19,282,011 8,377,608 13,422,664 58.3 64.6 31.2 36.0 
 
50-59 38,387,286 33,445,890 25,966,658 24,382,694 12,420,628 17,960,191 71.6 86.8 40.1 42.4 
 
40-49 40,256,515 37,814,866 26,563,430 27,171,684 13,693,085 20,079,753 72.8 96.0 40.0 41.6 
 
30-39 37,449,809 37,670,403 23,983,773 26,080,774 13,466,036 20,937,279 64.0 87.6 35.7 40.3 
 
20-29 23,642,281 29,095,710 17,085,836 22,074,358 6,556,445 12,151,207 44.7 57.8 21.6 31.4 
 
-19 22,957,857 37,645,690 17,144,067 25,875,712 5,813,790 20,054,405 58.4 139.7 17.7 28.6 
Sex 
           
 
Male 25,634,524 25,856,751 18,827,728 19,435,980 6,806,796 12,129,040 54.6 64.2 26.1 34.3 
 
Female 24,999,382 30,022,298 17,129,309 20,344,464 7,870,073 16,287,663 59.2 85.4 25.4 35.9 
Insurance Type 
          
 
Health Insurance 26,261,248 27,531,557 18,749,721 19,934,657 7,511,527 13,790,269 55.3 69.0 27.1 35.4 
 
Medical Aids 17,364,350 21,012,735 14,228,729 16,852,888 3,135,620 8,741,397 62.3 88.2 14.1 24.1 
Home-Oxygen Therapy 
          
 
User 44,213,803 36,614,213 28,229,403 27,003,477 15,984,400 20,867,394 80.6 97.8 47.4 44.5 
 




          
 
Disabled 32,688,017 32,009,151 25,211,065 26,388,580 7,476,952 12,166,779 77.7 86.0 35.2 47.6 
 
Non-disabled 25,394,983 27,075,384 18,284,581 19,646,825 7,110,402 13,478,213 55.8 70.9 25.8 34.6 
Diagnosed Year 
          
 
2005 22,883,645 24,958,570 16,753,140 18,537,920 6,130,505 11,809,171 51.4 67.0 25.4 34.4 
 
2006 25,741,740 27,485,463 18,423,879 19,704,136 7,317,861 13,839,963 57.2 71.5 26.1 34.7 
 
2007 27,462,222 28,413,411 19,670,472 20,628,710 7,791,750 14,409,751 58.8 73.8 26.1 35.0 
Death or F/U ends after Diagnosis 
          
 
Within a year 15,936,865 15,147,329 13,855,150 13,603,013 2,081,715 4,062,094 44.4 40.0 9.0 13.2 
 
During 1-1.99 yrs 37,062,947 25,781,070 26,594,289 21,727,652 10,468,658 11,153,466 80.8 71.8 36.1 27.9 
 
Within 2-2.99 yrs 48,494,424 34,357,305 31,084,050 26,709,814 17,410,374 18,091,506 94.2 97.1 53.1 37.9 
 
Within 3-3.99 yrs 56,994,155 43,412,652 34,431,861 32,423,843 22,562,295 23,424,679 107.8 137.0 66.0 50.0 
 
Within 4-4.99 yrs 54,945,330 47,440,079 33,582,326 33,751,059 21,363,004 26,838,742 106.0 155.3 65.8 53.7 
 
5 yrs Survivors 24,486,381 28,141,413 14,727,775 17,287,799 9,758,606 17,239,660 39.2 74.2 40.9 44.3 
 
2) Spending and utilization by patients’ time stages of lung cancer patients 
 
Table 11 shows healthcare spending and utilization by patients’ time stages of lung cancer and its percentage over episode spending and 
utilization. Relatively large portion of spending and utilization were occurred during first year of diagnosis and it is gradually decreased. 
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Table 11. Spending and utilization by time stage of nationwide 5 year follow-up 
lung cancer patients diagnosed during 2005-2007 
    Mean SD % over Total 
Total Spending 25,451,471 27,124,232 
 
 
First Year 17,433,075 15,647,295 68.5 
 
Second Year 4,046,166 9,830,290 15.9 
 
Third Year 2,009,032 7,119,801 7.9 
 
Fourth Year 1,179,830 5,509,786 4.6 
 
Firth Year 783,367 4,271,824 3.1 
     
Inpatient Spending 18,338,230 19,716,931 
 
 
First Year 13,713,507 13,415,800 74.8 
 
Second Year 2,415,270 7,324,551 13.2 
 
Third Year 1,119,131 5,136,979 6.1 
 
Fourth Year 664,619 4,115,162 3.6 
 
Firth Year 425,703 3,150,757 2.3 
     
Outpatient Spending 7,113,241 13,468,481 
 
 
First Year 3,719,568 6,049,480 52.3 
 
Second Year 1,630,896 4,890,604 22.9 
 
Third Year 889,901 3,777,989 12.5 
 
Fourth Year 515,212 2,810,157 7.2 
 
Firth Year 357,664 2,234,992 5.0 
     
Inpatient LOS 56.0 71.0 
 
 
First Year 39.9 41.3 71.4 
 
Second Year 8.2 26.9 14.7 
 
Third Year 3.9 20.2 6.9 
 
Fourth Year 2.4 16.9 4.2 
 
Firth Year 1.6 13.8 2.8 
     
Outpatient Days 25.9 34.7 
 
 
First Year 15.0 18.2 58.0 
 
Second Year 5.0 10.7 19.5 
 
Third Year 2.7 7.9 10.5 
 
Fourth Year 1.8 6.3 6.9 
 
Firth Year 1.3 5.7 5.2 
 
For example, total spending of KRW 17,433,075 were spent during first year which 
accounted for 68.5% of total spending KRW 25,451,471. Then total spending had 
gradually decreased as KRW 4,046,166 in second year which accounted for 15.9% of 
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total spending. KRW 2,009,032, KRW 1,179,830, and KRW 783,367 were reported 
mean total spending of third, fourth, and firth year of total spending respectively 
which accounted for 7.9%, 4.6%, and 3.1% of total spending. 
Inpatient spending of KRW 13,713,507 was spent during first year which accounted 
for 74.8% of total inpatient spending KRW 18,338,230. Then inpatient spending had 
gradually decreased as KRW 2,415,270 in second year which accounted for 13.2% of 
total inpatient spending. KRW 1,119,130, KRW 664,619, and KRW 425,703 were 
reported mean inpatient spending of third, fourth, and firth year of inpatient spending 
respectively which accounted for 6.1%, 3.6%, and 2.3% of total inpatient spending. 
Outpatient spending of KRW 3,719,568 was spent during first year which accounted 
for 52.3% of total outpatient spending KRW 7,113,241. Then outpatient spending had 
gradually decreased as KRW 1,630,896 in second year which accounted for 22.9% of 
total outpatient spending. KRW 889,901, KRW 515,212, and KRW 357,664 were 
reported mean outpatient spending of third, fourth, and firth year of outpatient 
spending respectively which accounted for 12.5%, 7.2%, and 5.0% of total outpatient 
spending. 
Inpatient utilization of 39.9 days was spent during first year which accounted for 
71.4% of total inpatient utilization 56.0 days. Then inpatient utilization had gradually 
decreased as 8.2 days in second year which accounted for 14.7% of total inpatient 
days. 3.9 days, 2.4 days, and 1.6 days were reported mean inpatient utilization of third, 
fourth, and firth year of inpatient utilization respectively which accounted for 6.9%, 
4.2%, and 2.8% of total inpatient utilization. 
Outpatient utilization of 15.0 days was spent during first year which accounted for 
58.0% of total outpatient utilization 25.9 days. Then outpatient utilization had 
gradually decreased as 5.0 days in second year which accounted for 19.5% of total 
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outpatient days. 2.7 days, 1.8 days, and 1.3 days were reported mean outpatient 
utilization of third, fourth, and firth year of outpatient utilization respectively which 
accounted for 10.5%, 6.9%, and 5.2% of total inpatient utilization. 
Table 11 and Table 12 shows that spending and utilization by time stage and duration 
of diagnosis to death of nationwide 5 year follow-up lung cancer patient diagnosed 
during 2005-2007 and percentage over total spending and utilization by time stage 
and duration of diagnosis to death of nationwide 5 year follow-up lung cancer patient 
diagnosed during 2005-2007.  
Lung cancer patients who died within a year of diagnosis, of course, had all of their 
spending and utilization in first year only. Patients who died during 1-1.99 years after 
lung cancer diagnosis had first year spending of KRW 25,441,399 and KRW 
11,621,448 in second year which accounted for 68.6% and 31.4% over total spending 
respectively. They also had first year inpatient spending of KRW 17,666,500 and 
KRW 89,927,790 in second year which accounted for 66.4% and 33.6% over total 
inpatient spending. First year of outpatient spending of KRW 7,774,899 and KRW 
2,693,758 in second year also identified which accounted for 74.3% and 25.7% over 
total outpatient spending. They also had first year inpatient utilization of 49.4 days 
and 31.4 days in second year which accounted for 61.2% and 38.8% over total 
inpatient utilization. First year of outpatient utilization of 27.4 days and 8.8 days in 
second year also identified which accounted for 75.8% and 24.2% over total 
outpatient utilization. Lung cancer patients who categorized into others, depending on 
duration of diagnosis to death, had relatively similar trend as patients presented above 
that lung cancer patient had significant portion of spending and utilization within very 
first year of their lung cancer time frame, then the portion gradually decreased. All 
others had similar trend but 5 years survivors. 
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Table 12. Spending and utilization by time stage and duration of diagnosis to death of nationwide 5 year follow-up lung cancer patient 
diagnosed during 2005-2007 
  
  
Duration of diagnosis to death or follow-up end 
  Within a year During 1-1.99 yrs During 2-2.99 yrs During 3-3.99 yrs During 4-4.99 yrs 5 yrs Survivors 
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Total Spending 
 First Year  15,936,865 15,147,329 25,441,399 18,584,195.0 20,577,473 15,614,808.4 19,245,118 15,048,269.7 16,094,304 13,690,352.3 13,854,271 11,998,449.7 
 Second Year  
  
11,621,548 13,470,536.1 16,721,318 17,078,777.7 11,133,191 14,005,287.8 7,366,263 11,697,671.0 2,770,847 6,447,111.0 
 Third Year  
    
11,195,632 13,090,936.0 15,562,364 17,222,489.2 8,930,688 13,225,812.7 2,563,160 6,690,725.0 
 Fourth Year  
      
11,053,483 14,017,790.5 12,504,727 16,407,655.6 2,533,863 6,936,309.4 
 Firth Year  
        
10,049,349 12,898,199.4 2,764,240 7,489,025.6 
Inpatient Spending 
 First Year  13,855,150 13,603,013 17,666,500 16,121,210.9 13,553,196 13,005,643.7 12,897,832 12,516,084.4 11,394,708 11,212,735.8 10,731,962 9,841,636.6 
 Second Year  
  
8,927,790 11,588,713.5 8,947,290 13,373,532.5 4,430,271 9,272,028.7 3,168,813 7,826,720.8 973,058 4,027,108.3 
 Third Year  
    
8,583,564 11,181,843.2 8,151,208 13,656,320.9 3,613,074 8,644,196.9 893,662 4,109,319.1 
 Fourth Year  
      
8,952,549 12,752,303.7 7,279,217 12,825,149.2 926,284 4,338,621.0 
 Firth Year  
        
8,126,515 11,458,486.1 1,202,810 5,161,150.2 
Outpatient Spending 
 First Year  2,081,715 4,062,094 7,774,899 8,384,907.1 7,024,277 8,111,162.5 6,347,285 7,553,974.8 4,699,596 6,579,725.3 3,122,310 4,816,443.1 
 Second Year  
  
2,693,758 4,850,720.3 7,774,029 9,979,043.1 6,702,920 9,836,173.0 4,197,450 7,888,669.0 1,797,790 4,279,109.1 
 Third Year  
    
2,612,068 4,957,386.4 7,411,156 9,994,854.6 5,317,614 9,522,610.9 1,669,498 4,623,862.7 
 Fourth Year  
      
2,100,934 4,023,370.1 5,225,510 8,716,787.7 1,607,579 4,774,978.4 
 Firth Year  
        
1,922,833 3,958,117.6 1,561,430 4,566,067.0 
Inpatient Days 
 First Year  44.4 40 49.4 52.9 34.3 41.8 32.5 39.7 28.1 34.9 25.6 28.4 
 Second Year  
  
31.4 39.5 29.5 52.1 13.8 40.4 10.0 34.2 3.1 17.0 
 Third Year  
    
30.4 39.7 29.0 59.2 11.9 41.3 2.8 17.2 
 Fourth Year  
      
32.5 47.2 26.5 57.2 3.2 20.6 
 Firth Year  
        
29.4 44.3 4.5 24.9 
Outpatient Days 
 First Year  9.0 13 27.4 21.6 24.8 20.7 23.9 21.0 19.5 19.1 15.6 17.6 
 Second Year  
  
8.8 12.2 19.9 17.2 16.6 16.4 11.7 12.2 7.4 10.3 
 Third Year  
    
8.3 11.6 18.1 18.6 12.7 14.0 6.2 9.0 
 Fourth Year  
      
7.4 10.7 14.8 17.0 5.9 9.7 
 Firth Year  
        




Table 13. % over total spending and utilization by time stage and duration of diagnosis to death of nationwide 5 year follow-up lung 
cancer patient diagnosed during 2005-2007 
    % over each spending and utilization by time frame and duration of diagnosis to death or follow-up end 
    Within a year During 1-1.99 yrs During 2-2.99 yrs During 3-3.99 yrs During 4-4.99 yrs 5 yrs Survivors 
Total Spending 
First Year 100 68.6 42.4 33.8 29.3 56.6 
Second Year 
 
31.4 34.5 19.5 13.4 11.3 
Third Year 
  
23.1 27.3 16.3 10.5 
Fourth Year 
   
19.4 22.8 10.3 
Firth Year 
    
18.3 11.3 
Inpatient Spending 
First Year 100 66.4 43.6 37.4 33.9 72.8 
Second Year 
 
33.6 28.8 12.9 9.4 6.6 
Third Year 
  
27.6 23.7 10.8 6.1 
Fourth Year 
   
26.0 21.7 6.3 
Firth Year 
    
24.2 8.2 
Outpatient Spending 
First Year 100 74.3 40.4 28.1 22.0 31.9 
Second Year 
 
25.7 44.6 29.7 19.6 18.5 
Third Year 
  
15.0 32.8 24.9 17.1 
Fourth Year 
   
9.3 24.5 16.5 
Firth Year 
    
9.0 16.0 
Inpatient Days 
First Year 100 61.2 36.4 30.1 26.5 65.1 
Second Year 
 
38.8 31.3 12.8 9.5 8.0 
Third Year 
  
32.3 26.9 11.2 7.3 
Fourth Year 
   
30.1 25.1 8.1 
Firth Year 
    
27.8 11.4 
Outpatient Days 
First Year 100 75.8 46.8 36.2 29.6 38.0 
Second Year 
 
24.2 37.6 25.2 17.8 18.2 
Third Year 
  
15.6 27.4 19.4 15.0 
Fourth Year 
   
11.2 22.5 14.4 
Firth Year 




5 years survivals had somewhat different trend that their spending and utilization 
had u-shape that the spending and utilization somewhat increased in firth year of their 
lung cancer time stage. They had first year spending of KRW 13,854,271 and KRW 
2,770,847 in second year, KRW 2,563,160 in third year, KRW 2,533,863 in fourth 
year, and KRW 2,764,240 in firth year which accounted for 56.6%, 11.3%, 10.5%, 
10.3%, and 11.3% over total spending respectively. As noted firth year spending was 
slightly increased in total spending. They also had first year inpatient spending of 
KRW 10,731,962, KRW 973,058 in second year, KRW 893,662 in third year, KRW 
926,284 in fourth year, and KRW 1,202,810 in firth year which accounted for 72.8%, 
6.6%, 6.1%, 6.3%, 8.2% over total inpatient spending respectively. First year of 
outpatient spending of KRW 3,122,310, KRW 1,797,790 in second year, KRW 
1,669,498 in third year, KRW 1,607,579 in fourth year, and KRW 1,561,430 in firth 
year which accounted for 31.9%, 18.5%, 17.1%, 16.5%, and 16.0% over total 
outpatient spending. 
They also had first year inpatient utilization of 25.6 days, 3.1 days in second year, 
2.8 days in third year, 3.2 days in fourth year, and 4.5 days in firth year which 
accounted for 65.1%, 8.0%, 7.3%, 8.1%, and 11.4% respectively over total inpatient 
utilization. First year of outpatient utilization of 15.6 days, 7.4 days in second year,  
6.2 days in third year, 5.9 days in fourth year, and 5.9 days in forth year also 
identified which accounted for 38.0%, 18.2%, 15.0%, 14.4%, and 14.5% over total 
outpatient utilization. As noted firth year spending and utilization increased as u-
shape. The figure 4 (Spending of 5 years survivors by time stage) and figure 5 
(Utilization of 5 years survivors by time stage) shows the trend of these u-shape. The 





Figure 5. Healthcare spending of 5 years survivors by time stage 
 
 




















































































































































3) Spending and utilization by periods before death and after diagnosis of 
lung cancer patients 
 
Table 14 depicts healthcare spending and utilization of 5 year follow-up lung 
cancer patients diagnosed during 2005-2007 by periods before follow-up ends. 
Real spending and utilization, and its percentage over episode are presented. 
Inpatient spending during last three months before follow-up end was KRW 
6,398,464 which was accounted for 34.9% of total inpatient spending. Inpatient 
spending during last six months and twelve months before follow-up end were 
KRW 9,107,200 and KRW 11,989,903 which accounted for 49.7% and 65.4% of 
total inpatient spending respectively. Inpatient LOS during last months before 
follow-up ends were also constituted large portions that 32.9%, 55.3%, and 70.7% 
for last 3, 6, 12 months before follow-up end respectively. 
 
Table 14. Healthcare spending and utilization of lung cancer patients by periods 
before follow-up end 
    Mean SD % over Total 
Inpatient Spending during 
Last 3 months 6,398,464 8,103,822 34.9 
Last 6 months 9,107,200 11,094,390 49.7 
Last 12 months 11,989,903 14,448,729 65.4 
Outpatient Spending during 
Last 3 months 753,572 1,600,079 10.6 
Last 6 months 1,718,097 3,248,743 24.2 
Last 12 months 3,230,939 5,986,534 45.4 
Inpatient LOS during 
Last 3 months 21.9 23.7 39.2 
Last 6 months 31.0 35.4 55.3 
Last 12 months 39.5 48.2 70.7 
Outpatient Days during 
Last 3 months 3.3 5.3 12.9 
Last 6 months 6.7 9.5 26.0 




Outpatient spending during last three months before follow-up end was KRW 
753,572 which was accounted for 10.6% of total outpatient spending. Outpatient 
spending during last six months and twelve months before follow-up end were KRW 
1,718,097 and KRW 3,230,939 which accounted for 24.2% and 45.4% of total 
outpatient spending respectively. Outpatient days during last months before follow-up 
ends were also constituted relatively large portions that 12.9%, 26.0%, and 44.8% for 
last 3, 6, 12 months before follow-up end respectively. 
Table 15 depicts healthcare spending and utilization of 5 year follow-up lung 
cancer patients diagnosed during 2005-2007 by periods after diagnosis of lung 
cancer. Real spending and utilization, and its percentage over episode are also 
presented. Inpatient spending during first three months after diagnosis was KRW 
8,897,402 which was accounted for 48.5% of total inpatient spending. Inpatient 
spending during first six months and twelve months after lung cancer diagnosis 
were KRW 11,283,409 and KRW 13,713,507 which accounted for 61.5% and 
74.8% of total inpatient spending respectively. Inpatient LOS during first months 
after diagnosis of lung cancer were also constituted large portions that 44.0% 
(24.6 days), 56.9% (31.9 days), and 71.4% (39.9 days) for last 3, 6, 12 months 
after diagnosis respectively. 
Outpatient spending during first three months after diagnosis was KRW 
1,484,083 which was accounted for 20.9% of total inpatient spending. Outpatient 
spending during first six months and twelve months after lung cancer diagnosis 
were KRW 2,417,594 and KRW 3,719,568 which accounted for 34.0% and 52.3% 
of total outpatient spending respectively. Outpatient days during first months after 
diagnosis of lung cancer were also constituted relative large portions that 24.8% 
(6.4 days), 40.0% (10.3 days), and 58.0% (15.0 days) for last 3, 6, 12 months after 
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diagnosis respectively. Outpatient spending and utilization were somewhat lower 
portions than inpatient spending and utilization, however, it is still high. 
 
Table 15. Healthcare spending and utilization of lung cancer patients by periods 
after diagnosis 
    Mean SD % over Total 
Inpatient Spending during 
First 3 months 8,897,402 8,169,473 48.5 
First 6 months 11,283,409 10,651,880 61.5 
First 12 months 13,713,507 13,415,800 74.8 
Outpatient Spending during 
First 3 months 1,484,083 2,599,499 20.9 
First 6 months 2,417,594 3,917,932 34.0 
First 12 months 3,719,568 6,049,480 52.3 
Inpatient LOS during 
First 3 months 24.6 22.4 44.0 
First 6 months 31.9 30.9 56.9 
First 12 months 39.9 41.3 71.4 
Outpatient Days during 
First 3 months 6.4 8.7 24.8 
First 6 months 10.3 12.9 40.0 
First 12 months 15.0 18.2 58.0 
 
Throughout the table 16 to table 19, the results of healthcare spending and 
utilization of lung cancer patients by periods before follow-up end and duration of 
diagnosis to death, healthcare spending and utilization of lung cancer patients by 
periods after diagnosis and duration of diagnosis to death, % over total healthcare 
spending and utilization of lung cancer patients by periods before follow-up end 
and duration of diagnosis to death, and % over healthcare spending and utilization 
of lung cancer patients by periods after diagnosis and duration of diagnosis to 
death were presented. Except 5 year survivors, most of lung cancer patient had 
significant portion of spending and utilization during last stage of their lung 
cancer. However, all types of patient had relatively large amount of spending and 




Table 16. Healthcare spending and utilization of lung cancer patients by periods before follow-up end and duration of diagnosis to death 
  
Duration of diagnosis to death or follow-up end 
Within a year Within a 
year 
During 1-1.99 yrs % over 
Total 
During 2-2.99 yrs % over 
Total Mean SD Mean SD Mean SD 
Inpatient Spending during 
Last 3 months 8,090,501 8,330,863 44.1 7,325,015 8,004,217 39.9 7,396,996 8,320,697 40.3 
Last 6 months 11,251,413 11,041,639 61.4 11,022,871 11,585,295 60.1 10,751,468 11,830,481 58.6 
Last 12 months 13,855,150 13,603,013 75.6 16,751,373 16,486,674 91.3 15,021,792 16,093,404 81.9 
Outpatient Spending during 
Last 3 months 748,863 1,543,839 10.5 1,216,753 1,982,936 17.1 1,109,334 1,913,235 15.6 
Last 6 months 1,499,120 2,865,003 21.1 3,183,464 4,234,299 44.8 2,945,758 4,233,778 41.4 
Last 12 months 2,081,715 4,062,094 29.3 7,066,346 8,136,667 99.3 7,056,826 8,770,198 99.2 
Inpatient LOS during 
Last 3 months 27.2 22.5 48.6 26.2 24.7 46.9 26.2 25.6 46.9 
Last 6 months 37.2 32.5 66.4 39.1 39.2 69.9 38.1 40.0 68.0 
Last 12 months 44.4 40.0 79.3 55.6 57.5 99.4 52.1 59.9 93.2 
Outpatient Days during 
Last 3 months 3.6 5.6 14.0 4.7 5.6 18.0 4.4 5.7 17.1 
Last 6 months 6.7 9.5 25.8 10.7 10.5 41.4 9.9 10.3 38.1 
Last 12 months 9.0 13.2 34.7 23.3 19.4 89.9 20.1 17.6 77.5 
    During 3-3.99 yrs % over 
Total 
During 4-4.99 yrs % over 
Total 
5 yrs Survivors % over 
Total     Mean SD Mean SD Mean SD 
Inpatient Spending during 
Last 3 months 7,417,062 8,850,793 40.4 6,575,512 8,494,179 35.9 794,118 3,642,307 4.3 
Last 6 months 10,734,628 12,984,551 58.5 9,382,381 11,542,194 51.2 1,239,027 4,987,924 6.8 
Last 12 months 14,715,106 17,462,675 80.2 12,806,285 15,943,524 69.8 1,916,604 7,071,027 10.5 
Outpatient Spending during 
Last 3 months 920,864 1,691,287 12.9 757,331 1,417,744 10.6 258,323 1,066,215 3.6 
Last 6 months 2,436,642 3,679,912 34.3 2,055,523 3,302,842 28.9 573,346 2,040,239 8.1 
Last 12 months 6,157,403 8,125,412 86.6 4,733,958 7,203,526 66.6 1,263,255 4,010,841 17.8 
Inpatient LOS during 
Last 3 months 25.6 26.6 45.8 23.2 25.9 41.4 2.9 12.0 5.1 
Last 6 months 38.4 44.0 68.6 34.4 42.3 61.5 4.7 19.7 8.4 
Last 12 months 52.6 67.7 94.0 47.0 65.6 83.9 7.3 31.6 13.1 
Outpatient Days during 
Last 3 months 3.7 5.2 14.3 3.7 5.3 14.2 1.1 3.0 4.2 
Last 6 months 8.5 9.6 32.8 7.9 9.8 30.4 2.3 5.6 9.1 





Table 17. Healthcare spending and utilization of lung cancer patients by periods after diagnosis and duration of diagnosis to death 
  
Duration of diagnosis to death or follow-up end 
Within a year % over 
Total 
During 1-1.99 yrs % over 
Total 
During 2-2.99 yrs % over 
Total Mean SD Mean SD Mean SD 
Inpatient Spending during 
First 3 months 9,224,051 8,935,073 50.3 8,598,118 7,481,783 46.9 8,402,078 7,536,005 45.8 
First 6 months 11,840,154 11,483,829 64.6 11,682,793 10,633,985 63.7 10,774,866 9,892,513 58.8 
First 12 months 13,855,150 13,603,013 75.6 17,666,500 16,121,211 96.3 13,553,196 13,005,644 73.9 
Outpatient Spending during 
First 3 months 1,108,077 2,172,835 15.6 2,262,737 3,097,518 31.8 2,325,756 3,242,897 32.7 
First 6 months 1,713,307 3,247,639 24.1 4,043,031 4,802,731 56.8 3,965,044 4,927,379 55.7 
First 12 months 2,081,715 4,062,094 29.3 7,774,899 8,384,907 99.3 7,024,277 8,111,163 98.7 
Inpatient LOS during 
First 3 months 28.4 24.6 50.7 21.8 20.6 39.0 20.4 19.5 36.5 
First 6 months 37.3 33.3 66.7 29.8 30.5 53.3 26.5 28.5 47.3 
First 12 months 44.4 40.0 79.3 49.4 52.9 88.4 34.3 41.8 61.3 
Outpatient Days during 
First 3 months 5.0 7.4 19.3 8.9 9.8 34.5 8.9 10.0 34.3 
First 6 months 7.5 10.8 29.1 15.6 14.3 60.2 15.2 14.7 58.7 
First 12 months 9.0 13.2 34.7 27.4 21.6 95.8 24.8 20.7 95.9 
    During 3-3.99 yrs % over 
Total 
During 4-4.99 yrs % over 
Total 
5 yrs Survivors % over 
Total     Mean SD Mean SD Mean SD 
Inpatient Spending during 
First 3 months 8,553,571 7,413,067 46.6 8,229,997 7,698,955 44.9 8,587,904 6,856,519 46.8 
First 6 months 10,878,640 9,983,356 59.3 10,129,789 9,701,658 55.2 9,908,074 8,547,258 54.0 
First 12 months 12,897,832 12,516,084 70.3 11,394,708 11,212,736 62.1 10,731,962 9,841,637 58.5 
Outpatient Spending during 
First 3 months 2,273,093 3,197,878 32.0 1,897,148 3,128,761 26.7 1,384,412 2,530,188 19.5 
First 6 months 3,840,495 4,871,859 54.0 3,005,927 4,415,232 42.3 2,141,158 3,500,568 30.1 
First 12 months 6,347,285 7,553,975 89.2 4,699,596 6,579,725 66.1 3,122,310 4,816,443 43.9 
Inpatient LOS during 
First 3 months 20.6 18.7 36.8 19.4 18.7 34.7 19.7 17.4 35.2 
First 6 months 26.1 27.4 46.7 24.1 25.6 43.1 23.1 22.8 41.2 
First 12 months 32.5 39.7 58.0 28.1 34.9 50.3 25.6 28.4 45.7 
Outpatient Days during 
First 3 months 9.0 10.4 34.7 8.0 10.3 30.7 6.8 9.3 26.1 
First 6 months 15.4 15.7 59.7 12.8 14.2 49.6 10.7 13.2 41.5 





Table 18. % over total healthcare spending and utilization of lung cancer patients by periods before follow-up end and duration of 
diagnosis to death 




1-1.99 yrs 2-2.99 yrs 3-3.99 yrs 4-4.99 yrs 
5 yrs 
Survivors 
Inpatient Spending during 
Last 3 months 34.9 44.1 39.9 40.3 40.4 35.9 4.3 
Last 6 months 49.7 61.4 60.1 58.6 58.5 51.2 6.8 
Last 12 months 65.4 75.6 91.3 81.9 80.2 69.8 10.5 
Outpatient Spending during 
Last 3 months 10.6 10.5 17.1 15.6 12.9 10.6 3.6 
Last 6 months 24.2 21.1 44.8 41.4 34.3 28.9 8.1 
Last 12 months 45.4 29.3 99.3 99.2 86.6 66.6 17.8 
Inpatient LOS during 
Last 3 months 39.2 48.6 46.9 46.9 45.8 41.4 5.1 
Last 6 months 55.3 66.4 69.9 68.0 68.6 61.5 8.4 
Last 12 months 70.7 79.3 99.4 93.2 94.0 83.9 13.1 
Outpatient Days during 
Last 3 months 12.9 14.0 18.0 17.1 14.3 14.2 4.2 
Last 6 months 26.0 25.8 41.4 38.1 32.8 30.4 9.1 
Last 12 months 44.8 34.7 89.9 77.5 68.9 59.8 18.8 
 
Table 19. % over healthcare spending and utilization of lung cancer patients by periods after diagnosis and duration of diagnosis to death 




1-1.99 yrs 2-2.99 yrs 3-3.99 yrs 4-4.99 yrs 
5 yrs 
Survivors 
Inpatient Spending during 
First 3 months 48.5 50.3 46.9 45.8 46.6 44.9 46.8 
First 6 months 61.5 64.6 63.7 58.8 59.3 55.2 54.0 
First 12 months 74.8 75.6 96.3 73.9 70.3 62.1 58.5 
Outpatient Spending during 
First 3 months 20.9 15.6 31.8 32.7 32.0 26.7 19.5 
First 6 months 34.0 24.1 56.8 55.7 54.0 42.3 30.1 
First 12 months 52.3 29.3 99.3 98.7 89.2 66.1 43.9 
Inpatient LOS during 
First 3 months 44.0 50.7 39.0 36.5 36.8 34.7 35.2 
First 6 months 56.9 66.7 53.3 47.3 46.7 43.1 41.2 
First 12 months 71.4 79.3 88.4 61.3 58.0 50.3 45.7 
Outpatient Days during 
First 3 months 24.8 19.3 34.5 34.3 34.7 30.7 26.1 
First 6 months 40.0 29.1 60.2 58.7 59.7 49.6 41.5 
First 12 months 58.0 34.7 95.8 95.9 92.3 75.4 60.2 
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3. Multivariate Analysis: Cox Proportional Hazard Model 
 
As shown in table 20, this study assessed the association between patient 
characteristics and their survival probability using Cox proportional hazard 
models after adjusting for all other covariates. This study found that no 
differences on hazard ratios by insurance type (Health insurance Vs. Medical aids) 
and diagnosed year, however, found significant differences among sex (Male Vs. 
Female), and age-group (higher in older than 30). 
 
Table 20. Cox-Proportional Hazard model for 5 years follow-up or dead lung 
cancer patients by their different types of characteristics 
    Hazard Ratio 95% HR CI Pr > ChiSq 
Age Group         
  80- 6.63 4.17 10.53 <.0001 
  70-79 4.34 2.74 6.90 <.0001 
  60-69 2.96 1.86 4.69 <.0001 
  50-59 2.27 1.43 3.60 <.0001 
  40-49 2.02 1.27 3.21 0.003 
  30-39 2.03 1.27 3.25 0.003 
  20-29 1.59 0.95 2.67 0.077 
  -19 1.00        
Sex           
  Female 0.74 0.73 0.76 <.0001 
  Male 1.00        
Insurance Type         
  Health Insurance 0.99 0.96 1.02 0.489 
  Medical Aids 1.00        
Diagnosed Year           
  2005 0.99 0.97 1.02 0.710 
  2006 1.01 0.99 1.04 0.301 
  2007 1.00        
Home-Oxygen Therapy         
  Non-User 1.05 0.99 1.12 0.116 
  User 1.00        
Respiratory Disability         
  Disabled 0.83 0.74 0.93 <.0001 
  Non-disabled 1.00        
ICU Days   1.01 1.01 1.01 <.0001 




Hazard ratio of age was somewhat greater in older age group strata, but no 
differences were found in 20-29 as compared to less than 19 (P=0.077). Hazard 
ratios were gradually increased as patient’s diagnosed age getting older (highest in 
age 80+, HR=6.63, P<0.001). Sex differences also found that female had greater 
survivals than male (HR=0.74, P<0.001). Respiratory disabled had greater 
survival than their counter parts; however, home-oxygen therapy users had 
indifferent survival probability than non-home-oxygen therapy users (P=0.116). 
Hazard ratio by diagnosis year of lung cancer showed also had non-significant 
association (year 2005 HR=0.99, P=0.0.710; year 2006 HR=1.01, P=0.301). 
Associations with individual utilization factor ICU days (HR=1.01), with survival 
of lung cancer patients was statistically significant, however, the effect was 
minimal. Ventilator days were not statistically significant with survival of lung 
cancer patients (P=0.552).  
Both unadjusted Kaplan Meier curves and figures of adjusted Cox-proportional 
hazard models to investigate association between individual factors and survival 




4. Multivariate Analysis: Linear Mixed Models 
 
Table 21 shows results of linear mixed models for association of various spending 
measures with individual and hospital level factors. Results of total spending by 
different age group strata showed that age with 80+ group had indifferent total 
spending as compared to less than 19 age group. Total spending was greatest in 50-59 
(61.0%) and very high in other mid-age groups (51.8% in 60-69, 50.1% in 40-49). 
Inpatient spending and outpatient spending had also similar trends by age group strata 
that indifferent inpatient and outpatient spending found among age group more than 
80 and age of 20-29 groups. The highest inpatient and outpatient spending also found 
in age group of 50-59 (47.8% greater), following 40-49 (inpatient: 38.3%, outpatient: 
81.8%) and 60-69 (inpatient: 71.9%, outpatient: 72.1%). Male was also associated 
with higher spending (total spending was 5.6%, inpatient spending was 5.4%, and 
outpatient spending was 9.3%) than its counterpart, female group. Health insurance 
holders had higher total spending of 2.9% than medical aids population but their 
inpatient spending was 2.8% lower although their outpatient spending 44.2% higher. 
Results for duration of diagnosis to death of lung cancer patients showed that 
patients who died during 1-3.99 years after lung cancer diagnosis had higher total 
spending (54.0%, 52.5%, and 43.5% respectively than 5 year survivors). Patient who 
died within a year of diagnosis had higher total spending but the amount was not very 
higher comparing to other groups. Inpatient spending also had similar trend, however, 
spending of patient who died within a year had relatively higher spending than 5 
years survivors. Total spending of patient who died within a year of diagnosis was not 
very high because of relatively very low outpatient spending among the group (118.1% 
less spending than 5 years survivors). Other groups for outpatient spending were 
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relative similar to total spending.  
Patients’ diagnosed year was also associated with total, inpatient, and outpatient 
spending that patient who diagnosed in 2005 had 22.9% lower and 9.3% lower for 
2006 diagnosed patient comparing to 2007 diagnosed patients. Inpatient and 
outpatient spending also had identical results. Home-oxygen therapy users had higher 
total (18.1%), inpatient (11.3%), and outpatient (30.4%) spending than non-users 
which all were statistically significant. Patient who received respiratory disability 
grading had both higher inpatient (10.3%) and outpatient (21.9%) spending, however, 
their total spending was not significantly different (3.2%, P=0.450) 
Other individual factors such as ICU days, ventilator days had also statistically 
significant spending increase as ICU days and ventilator days were increase but the 
effect was very minimal. However, repeated numbers of inpatient admissions were 
associated with higher total spending (8.2%), inpatient spending (8.6%), and 
outpatient spending (7.0%) as well.  
Although hospital structural variables (# of 100 Beds, Nurses per 100 beds, # of 
Specialist physician) were not statistically significant in order to determine total 
spending, inpatient spending, and outpatient spending, hospital type and hospital 
teaching status had statistically significant effect on the dependent variables. Teaching 
hospitals had higher total spending (35.6%), inpatient spending (32.8%), and 
outpatient spending (33.3%) which was all statistically significant. Large hospitals 
also had higher total spending (12.7%), inpatient spending (14.2%), and outpatient 
spending (4.4%) so as tertiary hospitals total spending (27.6%), inpatient spending 





Table 21. Results of linear mixed models for association of spending with 















      
  80- -0.040 0.745 -0.043 0.709 -0.283 0.294 
  70-79 0.280 0.021 0.232 0.045 0.276 0.303 
  60-69 0.518 <.0001 0.419 0.000 0.721 0.007 
  50-59 0.610 <.0001 0.478 <.0001 0.905 0.001 
  40-49 0.501 <.0001 0.383 0.001 0.818 0.002 
  30-39 0.432 0.001 0.307 0.010 0.768 <.0001 
  20-29 0.213 0.132 0.222 0.102 0.239 0.441 
  -19 Ref.  Ref.  Ref.  
Sex         
  Male 0.056 <.0001 0.054 <.0001 0.093 <.0001 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.029 0.036 -0.028 0.039 0.442 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 0.085 <.0001 0.258 <.0001 -1.181 <.0001 
  During 1-1.99 yrs 0.435 <.0001 0.400 <.0001 0.071 0.003 
  During 2-2.99 yrs 0.525 <.0001 0.385 <.0001 0.387 <.0001 
  During 3-3.99 yrs 0.540 <.0001 0.343 <.0001 0.528 <.0001 
  During 4-4.99 yrs 0.388 <.0001 0.246 <.0001 0.337 <.0001 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year         
  2005 -0.229 <.0001 -0.193 <.0001 -0.240 <.0001 
  2006 -0.093 <.0001 -0.085 <.0001 -0.052 0.004 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User 0.181 <.0001 0.113 <.0001 0.304 <.0001 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled 0.032 0.450 0.103 0.012 0.219 0.009 
  Non-disabled Ref.  Ref.  Ref.  
          
ICU Days 0.024 <.0001 0.026 <.0001 -0.003 0.060 
Ventilator Days 0.003 0.001 0.005 <.0001 0.001 0.618 
Number of Inpatient admissions 0.082 <.0001 0.086 <.0001 0.070 <.0001 
          
Teaching Status       
  Teaching 0.356 <.0001 0.328 <.0001 0.333 <.0001 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary  0.276 <.0001 0.337 <.0001 0.161 0.177 
  Large  0.127 <.0001 0.142 <.0001 0.044 0.552 
  Small Ref.  Ref.  Ref.  
        
# of 100 Beds 0.009 0.457 0.020 0.100 0.000 0.999 
Nurses per 100 beds 0.037 0.029 0.024 0.134 0.048 0.034 
# of Specialist physician 0.0004 0.394 0.0001 0.833 0.0008 0.231 




This study also examined ICC (intra-class correlation) in order to investigate 
reliability of multi-level modeling and the spending measure models showed that 
relatively higher ICC figures (10.03% for total spending, 10.00% for inpatient 
spending, and 5.56% for outpatient spending) that present significant portion of 
spending measures explained by hospital level factors.  
Table 22 shows results of linear mixed models for association of utilization 
measures with individual and hospital level factors. Results of inpatient utilization by 
different age group strata showed that age with 80+ group, age group of 20-29, and 
age group of 30-39 had indifferent inpatient LOS as compared to less than 19 of age 
group. Inpatient LOS was greatest in 50-59 (34.0%) and very high in other mid-age 
groups (25.0% in 70-79, 31.5% in 60-69, and 24.8% in 40-49). Outpatient utilization 
had also similar trends by age group strata that indifferent outpatient utilization found 
among age group more than 80 (P=0.397) and age of 20-29 group (P=0.324). The 
highest outpatient utilization also found in age group of 50-59 (65.8% greater), 
following age group of 60-69 (60.2%) and 40-49 (54.5%). Male was also associated 
with higher outpatient utilization (8.6%) than its counterpart, female group, however 
inpatient LOS was lower for male population (3.1% less, P<0.001). Health insurance 
holders had lower inpatient utilization of 16.9% than medical aids population but their 
outpatient utilization was 23.8% greater. 
Results for duration of diagnosis to death of lung cancer patients showed that 
patients who died had higher inpatient utilization (45.3%, 59.3%, 53.9%, 49.2%, 36.0% 
for duration of diagnosis to death within a year, during 1-2 years, during 2-3 years, 
during 3-4 years, during 4-5 years respectively) compared to 5 years survivors. 
Outpatient utilization was somewhat similar trend among patient who died during 2-5 
years of lung cancer diagnosis (11.2%, 23.7%, and 16.8% for duration of diagnosis to 
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death during 2-3 years, during 3-4 years, during 4-5 years respectively), however, 
inverse relationship also found that patient who died within a year of diagnosis to 
death (117.1% lower) and during 1-2 years (16.4% lower).  
Patients’ diagnosed year was also associated with inpatient utilization that patient 
who diagnosed in 2005 had 11.4% lower and 2.7% lower for 2006 diagnosed patient 
comparing to 2007 diagnosed patients. Outpatient utilization results showed that 
patient who diagnosed in 2005 had 2.4% lower and 2.2 higher 2006 diagnosed patient 
comparing to 2007 diagnosed patients, however, those results were not statistically 
significant. (P=0.059 and P=0.079). Home-oxygen therapy users had higher inpatient 
(13.1%) and outpatient (21.5%) utilization than non-users which all were statistically 
significant. Patient who received respiratory disability grading had higher inpatient 
utilization (19.4%), but lower outpatient utilization, however, this was not 
significantly different (1.5%, P=0.791). Other individual factors such as ICU days, 
ventilator days had mixed results for inpatient utilization measures but the effect was 
very minimal. Outpatient utilization for such factors was not statistically significant. 
However, repeated numbers of inpatient admissions were associated with higher 
inpatient utilization (8.8%) and outpatient utilization (5.3%) as well.  
Although hospital structural variables (# of 100 Beds, Nurses per 100 beds, # of 
Specialist physician) were not statistically significant in order to determine inpatient 
and outpatient utilization, hospital teaching status had statistically significant effect 
on the dependent variables. Teaching hospitals had higher inpatient utilization (13.4%) 
and outpatient utilization (21.9%). However, hospital type measure by tertiary, large, 
and small hospital was indifferent and not statistically significant. ICC of utilization 




Table 22. Results of linear mixed models for association of utilization with 
individual and hospital factors 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group           
  80- 0.035  0.776 0.156  0.397 
  70-79 0.250  0.042 0.389  0.035 
  60-69 0.315  0.010 0.602  0.001 
  50-59 0.340  0.006 0.658  0.000 
  40-49 0.248  0.045 0.545  0.003 
  30-39 0.153  0.225 0.588  0.002 
  20-29 0.091  0.527 0.210  0.324 
  -19 Ref.   Ref.   
Sex           
  Male -0.031  <.0001 0.086  <.0001 
  Female Ref.   Ref.   
Insurance Type         
  Health Insurance -0.169  <.0001 0.238  <.0001 
  Medical Aids Ref.   Ref.   
Death After Diagnosis         
  Within a year 0.453  <.0001 -1.171  <.0001 
  During 1-1.99 yrs 0.593  <.0001 -0.164  <.0001 
  During 2-2.99 yrs 0.539  <.0001 0.112  <.0001 
  During 3-3.99 yrs 0.492  <.0001 0.237  <.0001 
  During 4-4.99 yrs 0.360  <.0001 0.168  <.0001 
  5 yrs Survivors Ref.   Ref.   
Diagnosed Year           
  2005 -0.114  <.0001 -0.024  0.059 
  2006 -0.027  0.003 0.022  0.079 
  2007 Ref.   Ref.   
Home-Oxygen Therapy         
  User 0.131  <.0001 0.215  <.0001 
  Non-User Ref.   Ref.   
Respiratory Disability         
  Disabled 0.194  <.0001 0.015  0.791 
  Non-disabled Ref.   Ref.   
            
ICU Days   0.022  <.0001 -0.002  0.151 
Ventilator Days -0.002  0.016 -0.001  0.326 
Number of Inpatient admissions 0.088  <.0001 0.053  <.0001 
            
Teaching Status         
  Teaching 0.134  0.001 0.219  <.0001 
  Non-Teaching Ref.   Ref.   
Hospital Type         
  Tertiary  -0.034  0.594 0.107  0.146 
  Large  -0.072  0.046 0.079  0.101 
  Small Ref.   Ref.   
          
# of 100 Beds 0.026  0.009 -0.013  0.273 
Nurses per 100 beds 0.003  0.846 0.015  0.270 
# of Specialist physician -0.0007  0.087 0.0012  0.004 






1. Discussion of Study Methods 
 
In this study, we examined the association of individual and hospital level factors 
with healthcare spending and utilization of nationwide 5 years follow-up lung 
cancer patients using 2002-2012 health insurance claims data. Spending and 
utilization were measured mainly total, inpatient, and outpatient spending and 
inpatient LOS and outpatient days as utilization measures. The nationwide dataset 
over the decade used for the study included all lung cancer patients within the 
national health insurance program by following up their 60 months period after 
diagnosis of lung cancer. We used multi-level linear mixed models to compare 
individual and hospital level factors with spending and utilization of 5 years 
follow-up lung cancer patients. In order to investigate individual factors 
associated with survival probability of 5 year follow-up lung cancer patients, cox-
proportional hazard model were conducted.  
This study has several limitations worth noting, and caution must be taken when 
interpreting the study’s results or attempting to generalize its findings. Although 
we analyzed all nationwide inpatient claims for lung cancer during a defined 
period, South Korea’s unique health care delivery and insurance system may 
significantly limit the international generalizability of the results of this study. In 
addition healthcare spending and utilization of lung cancer care might depend 
upon the type of health insurance system in place and the ability of healthcare 
providers to negotiate the price of medical services. In this study, we assumed 
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spending using nationwide coverage rate of cancer patients, and applied the 
information into actual national health insurance claim data which might over or 
underestimate actual spending of nationwide lung cancer patients. Our study also 
suffered because we don’t have non-insurance covered services information, 
which is one of the most important spending factors. In order to overcome lack of 
the non-insurance covered services and their spending, we calculated the 
estimated spending and tried to match with figures of actual spending data. 
Also, given the nature of the health insurance claims dataset, this study 
artificially calculated the diagnosis time of lung cancer patients. Although we 
used the diagnosis information using the claim data, we are very confident that the 
diagnosis time in this study properly reflects the actual diagnosis of lung cancer 
patients because we observed all previous years’ claims and excluded first three 
years of claim information. We assumed that one who diagnosed with lung cancer 
might have health services utilization at least within 3 years. However, we still 
suffered from the lack of actual diagnosis date, further research using cohort 
datasets should be performed to inform the association examined in this study. In 
order to overcome the identification of lung cancer patients, we also had lists of 
selection and exclusion criteria to identify actual lung cancer patients. Our final 
study population was very robust that actual incidence cases reported by national 
cancer center and cases of our study are very similar (53,364 vs. 53,451), 
additionally the 5 year survival rate (about 20%).  
Furthermore, we investigated only patients with lung cancer. Therefore, our 
results will differ from those regarding healthcare spending and utilization of 
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patients with other types of cancer, possibly weakening the reliability of our 
findings.  
A lack of data with which to analyze important aspects of cancer patient was 
another limitation of our study. For example, we are not able to access to data that 
matching detailed information of cancer patients reported by national cancer 
center with health insurance claim data; hence we don’t have much clinical 
information regarding lung cancer patients. Although we included duration of 
diagnosis to death or end of follow-up in the analytic models, we still have 
limitation on such information. It would be much better to include in other studies 
for information of lung cancer stage, site of lung cancer, and type of lung cancer 
which may influence survival probability, spending and utilization of lung cancer 
population examined in this study.  
In addition, we don’t have detailed spending information in the claims data so 
we don’t know how much each patient spent healthcare resources for their cancer 
treatment which including surgery, chemotherapy, and so on. However, previous 
study conducted within a tertiary hospital in Korea found evidence that patient 
who survived more than 5 years spent about $32,000 in their lung cancer 
treatments22 which the amount is somewhat greater than our study. We assumed 
that the spending measure in this study pretty much solid based on the actual 
measure in the study, however, a study using cohort data should be implemented 
in order to investigate spending by various time stage of lung cancer patients.  
We also could not have information of detailed SES of each of lung cancer 
patients, for example annual income, education level, and other important 
variables which might influence treatments and outcomes which measured as 
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spending and utilization of lung cancer patients. Further studies should be 
conducted using the dataset that matching national health insurance claim data 
that including mentioned SES data with national cancer center’s cancer registry 
data or other sets of data contain such information. As noted this study doesn’t 
have SES variables, however, we have proxy measure that health insurance type 
(health insurance vs. medical aids) which explained differences in healthcare 
spending and utilization between the groups.  
Although we’re not able to access actual data on patient’s socio-economic status, 
proxy of the measure might explain that ―poorer health with more comorbidity 
and unhealthy behaviors, no or inadequate preventive health care and 
management of chronic conditions prior to cancer diagnosis, barriers to receiving 
treatment and adhering to a treatment regimen such as high cost, inability to 
navigate the health care system, misinformation about and mistrust of the health 
care system, lack of a usual source of health care, lack of transportation, lack of 
time off from work, no treatment or delay in receiving treatment‖67-70 Finally a 
lack of data with which to analyze other important aspects of lung cancer risk 
factors which may include smoking status, level of exercise, diet, sodium intake, 
exposure to virus and environmental situation of each patient etc is also one of 
limitations in this study. However, most of lung cancer patients are current or 
former smokers and they have relatively higher risk factors than others.  
Finally, we used total, inpatient, outpatient spending and utilization of each lung 
cancer patient that are relevant for policy research recommendations by 
examining information of total healthcare resources utilized. Zhao et al., however, 
suggested use of median cost and it confidence intervals when cost data collection 
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is incomplete due to study subjects’ right censoring issues are present.77 The 
methodology has not yet been adopted for health policy decision making, however, 
further studies are required to use such method when investigating healthcare 
spending and utilization of right censored data.  
Although several limitations of study design are presented, to the best of our 
knowledge, this is the one of few evaluations of nationwide trend of spending and 
utilization using nationwide health insurance claim including all lung cancer 
patients, further individual and hospital level factors that influences nationwide 
healthcare spending and utilization of lung cancer patients. We also examined 
factors associated with survival probability of lung cancer patients as well.  
We believe our findings will prove useful to health policy makers in South Korea 
and international readers especially those residing in countries with national 
health insurance programs based on fee-for-service payments. Our findings also 
add to mounting evidence of the need to develop a national cancer management 
strategy that reduce differences in use of healthcare resources and flexible 
healthcare benefits plan which might helpful to targeted sub population group.  
 
2. Discussion of Study Results 
 
In this study, descriptive results suggest evidences of spending and utilization 
among 5-years follow-up lung cancer patients that are including; 
  
 Increase in new lung cancer cases by years during 2005-2007 
 Increased spending and utilization nationwide during 2005-2007 
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 Higher proportion of spending & utilization during very first and last 
stage of lung cancer 
 Higher spending and utilization among non-survived population  
 No significant improvements of survival time during 2005 to 2007 
 
Increased spending and utilization could be huge economic and social burden of 
the society as a whole. In the previous research conducted by Park et al. examined 
that the average cost for treatment of one lung cancer patient for all 5 years was 
$32,708 which accounted for 44.7% of the per capita income during the same 5-
year period suggesting huge economic burden exists among lung cancer patient in 
this country.22  
Another argument would be expansion of cancer related policies that lung cancer 
patients were more likely to use inpatient and outpatient services as coverage 
expanded, hence overall healthcare spending increased due to higher utilization in 
lung cancer patients.18 In Korea, there are no restrictions on using primary, 
secondary, and tertiary medical institutions, and no penalties for repeated care. 
Without referrals for inpatient services, more services might be induced to both 
patients and providers.75 Escalating healthcare costs might be caused by 
unnecessary utilization and could be controlled by fixing reimbursement of annual 
copayments dependent on severity of cancer progression. Since payment is based 
on FFS in Korea, patients and providers lack incentives to reduce utilization. 
Government agencies alone can act to gauge national spending levels based on 
patient’s severity, types, and patterns of care, then set reasonable life time 
copayments limitations.18 Without the consideration of the proper policy, financial 
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viability of national health insurance program would be threatened by growing 
aging population. 
In order to prevent escalating health service use, we recommend considering 
policy changes for government agencies to maintain budget viability for the 
national health insurance program. First, a copayment flat rate might be the most 
attractive incentive for patients who make unnecessary outpatient visits and 
inpatient hospitalizations.18 This is also a great incentive to providers who are 
providing excessive unnecessary, expensive, and advanced tech services. The 
lessons from other studies show that increased cost-sharing decreases health care 
utilization.10,19 Different rates of copayments could be applied depending on types 
of cancer, years of cancer treatment period, cancer stage at diagnosis and costs of 
various health services. This strategy could help controlling the moral hazard of 
both patient and providers as well.18 However, coverage assurance to low-income 
population should be visible and limitation might not be allowed for such sub-
population group. Our study did not examine this income effects, future studies 
might have better arguments with this issue. 
Government agencies also need to focus on more on prevention, not just 
expanding coverage. Since the landmark reports showing that smoking causes 
lung cancer over a half century ago,78 expansion of smoking cessation programs 
should be first implemented. Furthermore, as our study confirmed, a large portion 
of healthcare spending occurs in the very end-of-life, so attention should be paid 
to palliative care, and development and expansion of facilities such as hospices 
that specialize in end of life care. Previous studies confirmed that hospice care 
reduces total healthcare costs for the majority of Medicare beneficiaries,79,80 and 
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studies conducted in Europe and the United States revealed that the availability of 
palliative care and hospice programs may help avoid patient hospitalization and 
reduce costs. It has also been suggested that establishment of palliative care 
programs is a way to improve the quality of life of terminally ill patients and their 
families and also to reduce utilization of expensive acute care hospital resources.81 
Although hospice care was first introduced in 1960s, but the reimbursement 
system for hospice care from the NHI is not available yet, instead it’s reimbursed 
as normal inpatient care where hospitals don’t have incentive to have hospice 
beds because it requires more resources than ordinary beds.82 Around 10% of 
cancer death used hospice care in this country; excess of demand over supply has 
been presented.83 Hospice care and palliative care are other areas which could use 
improvement, because there are an estimated 1 million cancer survivors, which 
accounted for 1.9% of the entire population in Korea, who have received life-
extending cancer treatment.84 In Korea, hospice care is only available at a limited 
number of hospitals and with a limited number of hospice beds (hospital N=44, 
total hospice beds=707). Expansion of hospice bed numbers within hospitals as 
well as specialized hospice care facilities is required for a financially viable NHI 
program, as it reduces overall lung cancer burden and provides a greater patient 
quality of life. 
The dataset we used, encompassing data from the last decade of all nationwide 
lung cancer inpatients as well as the hospitals where they were admitted, 
contributes to the robustness of our study. The increase in the number of adults 
living with advanced and complex chronic illnesses and the increase in 
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expenditures for these patients highlight the need for efficient models, such as 
palliative care that deliver quality services to complex patient populations.85 
Regarding the sex factor, difference has found in survival probability (hazard 
ratio was higher in male) but higher spending and outpatient utilization among 
male population, although lower inpatient utilization. Regarding the survival 
probability between male and female, previous research confirmed that the sex 
differences in tumor etiology may be influenced by physiological factors, such as 
the role of sex hormones, behavioral and environmental factors, such as levels of 
sun exposure or smoking habits.47 Further studies include such factors should be 
examined in order to find sex differences in this country as well. In the previous 
health services research literature has repeatedly documented that women utilize 
more medical care services than men at each point in the life cycle and thus 
generally have higher costs at each point as well39 and the cost differentials 
detected may also provide modest, indirect support for the argument that lung 
cancer in women is a different disease than it is in men.47 In this study, we also 
found evidences of higher spending and utilization among male population. 
Regarding the survival probability of deprived SES population, previous studies 
found evidences that the group had not only significantly lower survival time and 
lower access to care. Forrest et al. suggested that socioeconomic inequalities in 
receipt of treatment may exacerbate socioeconomic inequalities in incidence of 
lung cancer, which is strongly associated with higher smoking rates in more 
deprived populations, so may further contribute to the poorer outcomes in lower 
SES groups.48 Other studies also suggested that lower SES is associated with 
poorer housing, less social support, and a risk-promoting lifestyle, with a greater 
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likelihood of smoking.42 In this study we used medical aids group as proxy of 
deprived populations, and the study results suggested, however, survival 
probability of medical aids vs. health insurance was indifferent although spending 
and utilization were higher in health insurance population. Free access to health 
insurance covered care might increase survival of medical aids population; 
however, limited access for un-covered services might induce higher spending 
and utilization among health insurance population 
Demand for private health insurance plans by NHI members, which broadly 
cover medical expenses caused by catastrophic illness and accidents, is driven by 
the limited coverage and weak financial protection from the NHI benefit package. 
Private health insurance plans are both supplementary and complementary to the 
NHI plan by paying a lump-sum disbursement upon diagnosis of critical illness 
irrespective of actual medical bills and the receipt of care, or by providing 
itemized medical expenses compensation upon service use.86 Since economically 
vulnerable populations are less likely to have private health insurance to cover 
their cancer treatment costs, different levels of coverage rate should be 
implemented based on socio-economic status, especially depending on possession 
of private insurance among NHI members.18 In addition, restrictions on inpatient 
services by medical aids groups or high-tech outpatient services by health 
insurance holders should be considered as well. Somewhat interestingly, we found 
less spending and utilization among health insurance population group as 
compared to medical aids groups for inpatient services. Plausible reason might be 
NHI members were more likely to utilize relatively fast adoption of state-of-art 
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technologies under the outpatient basis; medical aids groups were more likely to 
use inpatient services because all inpatient services were covered. 
The results of our study also found evidences associated with lower survival 
among age with more than 40. As previous research noted that survival of 
relatively older age groups have lower survivals, we confirmed identical 
results.72,73 The results of this study also found that older age groups have higher 
hazard ratios, the highest hazard ratio was found in age 80+, however, highest 
spending and utilization was found among 50-59 was presented, although no 
difference of spending and utilization among age more than age more than 80. 
Health insurance coverage policies that consider age should be implemented as 
well in order to maintain financial viability of national health insurance program. 
Hospital characteristics especially for teaching status and hospital type rather 
than specific hospital structural variables (number of beds, physician, and nurse) 
associated with higher spending and utilization. Teaching hospitals were 
historically commanded high payment rates more than its counterparts in order to 
support their cost structure because of their reputations for providing high-quality 
healthcare, their specialized health service capacity, and education of medical 
students.52,53 Higher spending also found in tertiary and large hospitals in this 
study that they enforce their reputation as well. This study also confirmed the 
results of the previous research that the teaching hospitals had higher spending 
and utilization. The present results imply a significant impact of hospital teaching 
status and hospital types, on the healthcare spending and utilization among 
nationwide lung cancer patients. As conventional study suggested, large hospitals 
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may include a greater share of physicians, nurses, allied health professionals and 
other ancillary costs.54  
Summary of results in this study is presented in table 23 which contain results 
presented in this study by individual and hospital level factors of spending and 
utilization, further survival probability results. In sum, we found concrete results 
of differences in use of healthcare resources among individual and hospital factors 
that individual with health insurance, male, 40-79 age group and hospital type 
with tertiary and large, teaching had higher spending and utilization among 
nationwide lung cancer patients. The results of this also confirmed previous 
research that remaining questions regarding the cost-benefit of proven 
interventions measured by healthcare spending and utilization that rising costs are 
outpacing inflation rates and each nation’s budgetary level8 since we found 
evidences of inverse or indifferent survival probability with higher healthcare 
spending and utilization. 
 
Table 23. Summary of results 




 Lower Higher 
Diagnosed in year 2007 Higher Indifferent 
Health Insurance
†
 Higher Indifferent 
Male Higher Lower 
40+ Older Age Groups
‡




 Higher Higher 
Teaching Hospital Higher Higher 
Note: *Not highest in death within a year of diagnosis, †Lower for inpatient spending and utilization, 




Finally, this study suggests that efficient manner of healthcare spending and 
utilization policy should be implemented in order to maintain financial viability of 
national health insurance program. Finally, healthcare spending and utilization 
should be targeted to underserved population group that will ensure efficient locus 







Our retrospective cohort design study using nationwide health insurance claims 
data of past decade showed that increase in new lung cancer cases by years during 
2005-2007, increased spending and utilization nationwide during 2005-2007, no 
significant improvements of survival time, higher proportion of spending and 
utilization during very first and last stage of lung cancer, and higher spending and 
utilization among non-survived population.  
Using the multivariate analysis methods we found evidences of differences in 
use of healthcare resources among individual and hospital factors that individual 
with health insurance, male, 40-79 age group and hospital type with tertiary and 
large, teaching had higher spending and utilization, although survival of health 
insurance were indifferent, male and 40+ older age group had relatively lower in 
their survivals among nationwide 5 years follow-up lung cancer patients.  
As inverse relationship between survivals probability with healthcare spending 
and utilization, this study might suggest that efficient manner of healthcare policy 
implementation for patients’ spending and utilization in order to maintain 
financial viability of national health insurance program that the allocation of 
limited health-care resources demands an agreed rational allocation principle, and 
consequently priority setting is of considerable importance.  
Moreover, healthcare spending and utilization considered to be targeted to under-
served population groups that will ensure efficient locus of healthcare service 
delivery by accounting for survival probability of different sub-population group. 
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Results of this study might be useful to health policy makers not only in South 
Korea but also international readers that need to develop a national cancer 
management strategy that reduce differences in healthcare resources and flexible 
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Appendix A. Supplementary figures for Survival Analysis 
 
A-1. Unadjusted Kaplan Meier curves: Association between individual factors 
and survival among 5 years follow-up lung cancer patients 
 








A-1-2. Sex: Male Vs. Female 
  
A-1-3. Age group Strata 
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A-1-4. Respiratory disabled Vs. Respiratory Non-disabled 
 
A-1-5. Home-oxygen therapy user Vs. Home-oxygen therapy Non-user 
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A-2. Adjusted Cox-Proportional Hazard Models: Association between individual 
factors and survival among 5 years follow-up lung cancer patients 
 
A-2-1. Health Insurance Vs. Medical Aids 
 
A-2-2. Sex: Male Vs. Female 
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A-2-3. Age group Strata 
 
A-2-4. Respiratory disabled Vs. Respiratory Non-disabled 
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Appendix B. Distribution of Dependent Variables 
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Appendix C. Results of Linear Mixed Models for periods before death 
 
 C-1. Healthcare spending and utilization of 5 years follow-up 
lung cancer patients during last 3 months before follow-up end 
 
 C-2. Healthcare spending and utilization of 5 years follow-up 
lung cancer patients during last 6 months before follow-up end 
 
 C-3. Healthcare spending and utilization of 5 years follow-up 




















Age Group             
  80- -0.316 0.360 -0.772 0.005 0.462 0.423 
  70-79 -0.069 0.842 -0.623 0.022 0.865 0.133 
  60-69 0.127 0.711 -0.447 0.101 1.220 0.034 
  50-59 0.275 0.424 -0.315 0.249 1.399 0.015 
  40-49 0.346 0.315 -0.284 0.298 1.454 0.012 
  30-39 0.420 0.228 -0.249 0.366 1.538 0.008 
  20-29 0.053 0.890 -0.145 0.632 1.042 0.093 
  -19 Ref.  Ref.  Ref.  
Sex 
 
      
  Male -0.023 0.122 0.021 0.067 0.064 0.002 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.011 0.658 -0.010 0.575 0.347 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 2.777 <.0001 0.613 <.0001 0.888 <.0001 
  During 1-1.99 yrs 2.288 <.0001 0.353 <.0001 1.008 <.0001 
  During 2-2.99 yrs 2.131 <.0001 0.325 <.0001 0.835 <.0001 
  During 3-3.99 yrs 2.012 <.0001 0.310 <.0001 0.656 <.0001 
  During 4-4.99 yrs 1.855 <.0001 0.299 <.0001 0.499 <.0001 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year 
 
      
  2005 -0.166 <.0001 -0.174 <.0001 -0.145 <.0001 
  2006 -0.052 0.001 -0.067 <.0001 -0.047 0.026 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User 0.205 <.0001 0.006 0.855 0.195 0.000 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled 0.003 0.967 -0.054 0.351 0.021 0.832 
  Non-disabled Ref.  Ref.  Ref.  
  
 
      
ICU Days 0.013 <.0001 0.016 <.0001 -0.012 <.0001 
Ventilator Days 0.022 <.0001 0.017 <.0001 0.003 0.225 
Number of Inpatient admissions 0.057 <.0001 0.027 <.0001 0.020 <.0001 
  
 
      
Teaching Status       
  Teaching 0.156 <.0001 0.249 <.0001 0.315 <.0001 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary 0.138 0.015 0.253 <.0001 0.059 0.396 
  Large 0.084 0.051 0.115 0.002 0.115 0.077 
  Small Ref.  Ref.  Ref.  
 
      
# of 100 Beds 0.012 0.144 0.012 0.170 -0.019 <.0001 
Nurses per 100 beds 0.016 0.055 0.013 0.222 0.019 <.0001 




C-1-2. Healthcare utilization during last 3 months before follow-up end 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group           
  80- -0.460 0.100 0.460 0.143 
  70-79 -0.346 0.215 0.554 0.077 
  60-69 -0.314 0.260 0.654 0.037 
  50-59 -0.242 0.386 0.667 0.033 
  40-49 -0.232 0.408 0.650 0.038 
  30-39 -0.254 0.369 0.706 0.025 
  20-29 -0.110 0.723 0.588 0.082 
  -19 Ref.  Ref.  
Sex       
  Male -0.088 <.0001 0.032 0.005 
  Female Ref.  Ref.  
Insurance Type     
  Health Insurance -0.137 <.0001 0.171 <.0001 
  Medical Aids Ref.  Ref.  
Death After Diagnosis     
  Within a year 0.558 <.0001 0.550 <.0001 
  During 1-1.99 yrs 0.406 <.0001 0.546 <.0001 
  During 2-2.99 yrs 0.358 <.0001 0.475 <.0001 
  During 3-3.99 yrs 0.315 <.0001 0.354 <.0001 
  During 4-4.99 yrs 0.296 <.0001 0.338 <.0001 
  5 yrs Survivors Ref.  Ref.  
Diagnosed Year       
  2005 -0.118 <.0001 0.026 0.027 
  2006 -0.027 0.029 0.020 0.089 
  2007 Ref.  Ref.  
Home-Oxygen Therapy     
  User -0.0003 0.993 0.153 <.0001 
  Non-User Ref.  Ref.  
Respiratory Disability     
  Disabled -0.081 0.169 0.030 0.583 
  Non-disabled Ref.  Ref.  
        
ICU Days   0.015 <.0001 -0.006 <.0001 
Ventilator Days 0.003 0.010 -0.001 0.525 
Number of Inpatient admissions 0.033 <.0001 0.014 <.0001 
        
Teaching Status     
  Teaching 0.060 0.035 0.066 0.038 
  Non-Teaching Ref.  Ref.  
Hospital Type     
  Tertiary  -0.035 0.286 0.007 0.854 
  Large  -0.060 0.062 0.055 0.119 
  Small Ref.  Ref.  
      
# of 100 Beds 0.018 0.004 -0.015 0.029 
Nurses per 100 beds 0.004 0.596 0.004 0.548 


















Age Group               
  80- 0.042 0.871 -0.589 0.023 0.312 0.415 
  70-79 0.348 0.177 -0.363 0.161 0.778 0.042 
  60-69 0.559 0.030 -0.167 0.519 1.212 0.002 
  50-59 0.670 0.009 -0.041 0.875 1.389 <.0001 
  40-49 0.728 0.005 -0.016 0.951 1.445 <.0001 
  30-39 0.761 0.004 0.005 0.984 1.618 <.0001 
  20-29 0.619 0.035 0.206 0.473 1.256 0.004 
  -19 Ref.  Ref.  Ref.  
Sex         
  Male -0.048 <.0001 -0.004 0.704 0.043 0.028 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.029 0.170 -0.024 0.166 0.380 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 2.991 <.0001 0.940 <.0001 1.193 <.0001 
  During 1-1.99 yrs 2.536 <.0001 0.620 <.0001 1.534 <.0001 
  During 2-2.99 yrs 2.319 <.0001 0.507 <.0001 1.309 <.0001 
  During 3-3.99 yrs 2.116 <.0001 0.429 <.0001 1.004 <.0001 
  During 4-4.99 yrs 1.933 <.0001 0.389 <.0001 0.869 <.0001 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year         
  2005 -0.147 <.0001 -0.179 <.0001 -0.159 <.0001 
  2006 -0.049 <.0001 -0.067 <.0001 -0.055 0.006 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User 0.305 <.0001 0.085 0.005 0.255 <.0001 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled 0.097 0.129 -0.055 0.322 0.270 0.004 
  Non-disabled Ref.  Ref.  Ref.  
          
ICU Days   0.013 <.0001 0.019 <.0001 -0.010 <.0001 
Ventilator Days 0.018 <.0001 0.015 <.0001 0.005 0.026 
Number of Inpatient admissions 0.075 <.0001 0.047 <.0001 0.045 <.0001 
          
Teaching Status       
  Teaching 0.215 <.0001 0.255 <.0001 0.269 <.0001 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary  0.207 <.0001 0.259 <.0001 0.081 0.442 
  Large  0.109 <.0001 0.155 <.0001 0.004 0.953 
  Small Ref.  Ref.  Ref.  
        
# of 100 Beds 0.021 0.021 0.022 0.031 0.009 0.559 
Nurses per 100 beds 0.017 0.101 0.014 0.280 0.027 0.119 
# of Specialist physician -0.0004 0.200 -0.0003 0.472 0.0005 0.376 
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C-2-2. Healthcare utilization during last 6 months before follow-up end 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group         
  80- -0.462 0.089 0.443 0.055 
  70-79 -0.274 0.313 0.621 0.007 
  60-69 -0.219 0.421 0.786 0.001 
  50-59 -0.145 0.594 0.820 <.0001 
  40-49 -0.134 0.623 0.796 0.001 
  30-39 -0.159 0.565 0.893 <.0001 
  20-29 0.001 0.997 0.765 0.003 
  -19 Ref.  Ref.  
Sex       
  Male -0.112 <.0001 0.035 0.003 
  Female Ref.  Ref.  
Insurance Type     
  Health Insurance -0.141 <.0001 0.203 <.0001 
  Medical Aids Ref.  Ref.  
Death After Diagnosis     
  Within a year 0.850 <.0001 0.753 <.0001 
  During 1-1.99 yrs 0.661 <.0001 0.952 <.0001 
  During 2-2.99 yrs 0.543 <.0001 0.826 <.0001 
  During 3-3.99 yrs 0.455 <.0001 0.637 <.0001 
  During 4-4.99 yrs 0.414 <.0001 0.619 <.0001 
  5 yrs Survivors Ref.  Ref.  
Diagnosed Year       
  2005 -0.120 <.0001 0.032 0.011 
  2006 -0.022 0.070 0.026 0.032 
  2007 Ref.  Ref.  
Home-Oxygen Therapy     
  User 0.0692 0.028 0.236 <.0001 
  Non-User Ref.  Ref.  
Respiratory Disability     
  Disabled -0.096 0.099 0.052 0.358 
  Non-disabled Ref.  Ref.  
        
ICU Days   0.017 <.0001 -0.006 <.0001 
Ventilator Days 0.002 0.045 0.002 0.250 
Number of Inpatient admissions 0.050 <.0001 0.028 <.0001 
        
Teaching Status     
  Teaching 0.093 <.0001 0.201 <.0001 
  Non-Teaching Ref.  Ref.  
Hospital Type     
  Tertiary  -0.058 0.262 0.053 0.358 
  Large  -0.083 0.019 0.041 0.336 
  Small Ref.  Ref.  
      
# of 100 Beds 0.020 <.0001 -0.015 <.0001 
Nurses per 100 beds 0.004 0.067 0.002 0.301 


















Age Group             
  80- 0.304 0.150 -0.316 0.167 0.283 0.421 
  70-79 0.639 0.003 -0.047 0.837 0.795 0.024 
  60-69 0.861 <.0001 0.162 0.477 1.261 <.0001 
  50-59 0.963 <.0001 0.280 0.221 1.451 <.0001 
  40-49 0.980 <.0001 0.281 0.219 1.469 <.0001 
  30-39 1.019 <.0001 0.277 0.232 1.619 <.0001 
  20-29 0.806 0.001 0.301 0.237 1.213 0.002 
  -19 Ref.  Ref.  Ref.  
Sex         
  Male -0.037 0.002 0.010 0.355 0.023 0.217 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.043 0.025 -0.036 0.030 0.411 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 2.776 <.0001 1.198 <.0001 0.908 <.0001 
  During 1-1.99 yrs 2.568 <.0001 0.946 <.0001 1.796 <.0001 
  During 2-2.99 yrs 2.280 <.0001 0.691 <.0001 1.580 <.0001 
  During 3-3.99 yrs 2.069 <.0001 0.557 <.0001 1.291 <.0001 
  During 4-4.99 yrs 1.768 <.0001 0.458 <.0001 0.996 <.0001 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year         
  2005 -0.177 <.0001 -0.162 <.0001 -0.230 <.0001 
  2006 -0.101 <.0001 -0.065 <.0001 -0.115 <.0001 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User 0.344 <.0001 0.168 <.0001 0.305 <.0001 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled -0.018 0.750 -0.120 0.018 0.286 0.002 
  Non-disabled Ref.  Ref.  Ref.  
          
ICU Days 0.013 <.0001 0.019 <.0001 -0.007 <.0001 
Ventilator Days 0.014 <.0001 0.012 <.0001 0.003 0.077 
Number of Inpatient admissions 0.088 <.0001 0.069 <.0001 0.059 <.0001 
          
Teaching Status       
  Teaching 0.283 <.0001 0.279 <.0001 0.301 <.0001 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary  0.228 <.0001 0.290 <.0001 0.122 0.276 
  Large  0.093 0.023 0.154 <.0001 0.022 0.776 
  Small Ref.  Ref.  Ref.  
        
# of 100 Beds 0.019 0.065 0.023 0.035 0.006 0.721 
Nurses per 100 beds 0.019 0.114 0.016 0.267 0.032 0.111 
# of Specialist physician -0.0001 0.716 -0.0001 0.725 0.0006 0.307 
100 
 
C-3-2. Healthcare utilization during last 12 months before follow-up end 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group         
  80- -0.224  0.360 0.418  0.062 
  70-79 -0.001  0.995 0.614  0.006 
  60-69 0.077  0.754 0.803  <.0001 
  50-59 0.146  0.549 0.841  <.0001 
  40-49 0.129  0.599 0.805  <.0001 
  30-39 0.089  0.720 0.875  <.0001 
  20-29 0.097  0.721 0.675  0.008 
  -19 Ref.   Ref.   
Sex           
  Male -0.097  <.0001 0.025  0.038 
  Female Ref.   Ref.   
Insurance Type         
  Health Insurance -0.145  <.0001 0.192  <.0001 
  Medical Aids Ref.   Ref.   
Death After Diagnosis         
  Within a year 1.081  <.0001 0.602  <.0001 
  During 1-1.99 yrs 0.928  <.0001 1.279  <.0001 
  During 2-2.99 yrs 0.706  <.0001 1.056  <.0001 
  During 3-3.99 yrs 0.559  <.0001 0.843  <.0001 
  During 4-4.99 yrs 0.470  <.0001 0.732  <.0001 
  5 yrs Survivors Ref.   Ref.   
Diagnosed Year           
  2005 -0.108  <.0001 -0.006  0.650 
  2006 -0.015  0.197 -0.004  0.764 
  2007 Ref.   Ref.   
Home-Oxygen Therapy         
  User 0.1499  <.0001 0.239  <.0001 
  Non-User Ref.   Ref.   
Respiratory Disability         
  Disabled -0.144  0.008 0.063  0.280 
  Non-disabled Ref.   Ref.   
            
ICU Days 0.018  <.0001 -0.005  <.0001 
Ventilator Days 0.002  0.126 0.001  0.564 
Number of Inpatient admissions 0.069  <.0001 0.044  <.0001 
            
Teaching Status         
  Teaching 0.134  <.0001 0.158  <.0001 
  Non-Teaching Ref.   Ref.   
Hospital Type         
  Tertiary  -0.024  0.435 0.085  0.190 
  Large  -0.062  0.026 0.046  0.243 
  Small Ref.   Ref.   
          
# of 100 Beds 0.018  <.0001 -0.008  0.396 
Nurses per 100 beds 0.002  0.333 0.004  0.747 
# of Specialist physician -0.0007  <.0001 0.0010  0.003 
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Appendix D. Results of Linear Mixed Models for periods after diagnosis 
 
 D-1. Healthcare spending and utilization of 5 years follow-up 
lung cancer patients during first 3 months after diagnosis 
 
 D-2. Healthcare spending and utilization of 5 years follow-up 
lung cancer patients during first 6 months after diagnosis  
 
 D-3. Healthcare spending and utilization of 5 years follow-up 


















Age Group             
  80- -0.034 0.832 -0.149 0.262 -0.055 0.848 
  70-79 0.218 0.167 0.094 0.476 0.371 0.197 
  60-69 0.453 0.004 0.274 0.038 0.696 0.016 
  50-59 0.515 0.001 0.304 0.022 0.814 0.005 
  40-49 0.455 0.004 0.219 0.098 0.766 0.008 
  30-39 0.396 0.015 0.138 0.308 0.831 0.005 
  20-29 0.222 0.231 0.058 0.706 0.288 0.380 
  -19 Ref.  Ref.  Ref.  
Sex         
  Male 0.077 <.0001 0.076 <.0001 0.177 <.0001 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.243 <.0001 0.005 0.748 0.375 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 0.357 <.0001 0.151 <.0001 0.171 <.0001 
  During 1-1.99 yrs -0.014 0.410 -0.130 <.0001 0.478 <.0001 
  During 2-2.99 yrs -0.130 <.0001 -0.183 <.0001 0.373 <.0001 
  During 3-3.99 yrs -0.193 <.0001 -0.197 <.0001 0.347 <.0001 
  During 4-4.99 yrs -0.402 <.0001 -0.219 <.0001 0.044 0.384 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year         
  2005 -0.278 <.0001 -0.184 <.0001 -0.252 <.0001 
  2006 -0.136 <.0001 -0.105 <.0001 -0.056 0.002 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User -0.024 0.460 -0.008 0.778 0.145 0.003 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled 0.070 0.208 -0.106 0.019 0.222 0.009 
  Non-disabled Ref.  Ref.  Ref.  
          
ICU Days 0.026 <.0001 0.026 <.0001 -0.003 0.164 
Ventilator Days -0.004 <.0001 -0.003 0.002 0.005 0.005 
Number of Inpatient admissions 0.045 <.0001 0.037 <.0001 0.028 <.0001 
          
Teaching Status       
  Teaching 0.387 <.0001 0.318 <.0001 0.176 0.018 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary  0.379 <.0001 0.309 <.0001 0.072 0.552 
  Large  0.154 0.002 0.132 <.0001 -0.014 0.849 
  Small Ref.  Ref.  Ref.  
        
# of 100 Beds 0.007 0.640 0.020 0.073 -0.011 0.562 
Nurses per 100 beds 0.038 0.041 0.017 0.260 0.060 0.009 




D-1-2. Healthcare utilization during first 3 months after lung cancer diagnosis 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group         
  80- -0.059  0.654 -0.088  0.615 
  70-79 0.116  0.378 0.051  0.771 
  60-69 0.199  0.130 0.184  0.293 
  50-59 0.207  0.115 0.229  0.192 
  40-49 0.125  0.344 0.175  0.320 
  30-39 0.010  0.943 0.199  0.267 
  20-29 -0.034  0.821 -0.085  0.669 
  -19 Ref.   Ref.   
Sex           
  Male 0.011  0.194 0.122  <.0001 
  Female Ref.   Ref.   
Insurance Type         
  Health Insurance -0.124  <.0001 0.185  <.0001 
  Medical Aids Ref.   Ref.   
Death After Diagnosis         
  Within a year 0.306  <.0001 0.005  0.709 
  During 1-1.99 yrs -0.042  0.002 0.201  <.0001 
  During 2-2.99 yrs -0.121  <.0001 0.130  <.0001 
  During 3-3.99 yrs -0.135  <.0001 0.109  <.0001 
  During 4-4.99 yrs -0.183  <.0001 -0.042  0.173 
  5 yrs Survivors Ref.   Ref.   
Diagnosed Year           
  2005 -0.093  <.0001 -0.042  <.0001 
  2006 -0.029  0.002 0.011  0.318 
  2007 Ref.   Ref.   
Home-Oxygen Therapy         
  User -0.0031  0.908 0.077  0.009 
  Non-User Ref.   Ref.   
Respiratory Disability         
  Disabled -0.223  <.0001 0.045  0.387 
  Non-disabled Ref.   Ref.   
            
ICU Days 0.020  <.0001 -0.001  0.212 
Ventilator Days -0.004  <.0001 0.001  0.417 
Number of Inpatient admissions 0.033  <.0001 0.020  <.0001 
            
Teaching Status         
  Teaching 0.109  0.005 0.089  0.030 
  Non-Teaching Ref.   Ref.   
Hospital Type         
  Tertiary  -0.086  0.185 0.055  0.402 
  Large  -0.079  0.034 0.067  0.123 
  Small Ref.   Ref.   
          
# of 100 Beds 0.026  0.011 -0.016  0.125 
Nurses per 100 beds -0.006  0.628 0.007  0.535 


















Age Group             
  80- -0.143 0.336 -0.152 0.240 -0.026 0.927 
  70-79 0.149 0.313 0.119 0.358 0.468 0.092 
  60-69 0.414 0.005 0.326 0.012 0.866 0.002 
  50-59 0.491 0.001 0.368 0.005 0.994 <.0001 
  40-49 0.404 0.007 0.265 0.041 0.944 0.001 
  30-39 0.334 0.028 0.196 0.139 1.032 0.000 
  20-29 0.241 0.165 0.116 0.438 0.589 0.065 
  -19 Ref.  Ref.  Ref.  
Sex         
  Male 0.089 <.0001 0.090 <.0001 0.172 <.0001 
  Female Ref.  Ref.  Ref.  
Insurance Type       
  Health Insurance 0.172 <.0001 0.003 0.866 0.385 <.0001 
  Medical Aids Ref.  Ref.  Ref.  
Death After Diagnosis       
  Within a year 0.493 <.0001 0.288 <.0001 0.080 <.0001 
  During 1-1.99 yrs 0.133 <.0001 -0.054 <.0001 0.573 <.0001 
  During 2-2.99 yrs -0.071 0.001 -0.180 <.0001 0.398 <.0001 
  During 3-3.99 yrs -0.169 <.0001 -0.237 <.0001 0.320 <.0001 
  During 4-4.99 yrs -0.423 <.0001 -0.282 <.0001 -0.037 0.464 
  5 yrs Survivors Ref.  Ref.  Ref.  
Diagnosed Year         
  2005 -0.267 <.0001 -0.197 <.0001 -0.275 <.0001 
  2006 -0.122 <.0001 -0.097 <.0001 -0.072 <.0001 
  2007 Ref.  Ref.  Ref.  
Home-Oxygen Therapy       
  User 0.014 0.660 -0.023 0.393 0.179 <.0001 
  Non-User Ref.  Ref.  Ref.  
Respiratory Disability       
  Disabled 0.085 0.103 -0.091 0.045 0.260 0.002 
  Non-disabled Ref.  Ref.  Ref.  
          
ICU Days 0.028 <.0001 0.029 <.0001 -0.003 0.048 
Ventilator Days -0.004 <.0001 -0.003 0.005 0.004 0.043 
Number of Inpatient admissions 0.060 <.0001 0.054 <.0001 0.044 <.0001 
          
Teaching Status       
  Teaching 0.392 <.0001 0.333 <.0001 0.263 <.0001 
  Non-Teaching Ref.  Ref.  Ref.  
Hospital Type       
  Tertiary  0.325 <.0001 0.335 <.0001 0.127 0.280 
  Large  0.119 0.013 0.133 <.0001 0.006 0.931 
  Small Ref.  Ref.  Ref.  
        
# of 100 Beds 0.011 0.425 0.021 0.072 -0.007 0.727 
Nurses per 100 beds 0.040 0.035 0.019 0.214 0.056 0.013 




D-2-2. Healthcare utilization during first 6 months after lung cancer diagnosis 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group         
  80- -0.099  0.448 0.054  0.765 
  70-79 0.104  0.426 0.248  0.170 
  60-69 0.205  0.116 0.437  0.016 
  50-59 0.223  0.088 0.484  0.008 
  40-49 0.115  0.380 0.414  0.023 
  30-39 0.014  0.915 0.438  0.018 
  20-29 -0.029  0.850 0.217  0.297 
  -19 Ref.   Ref.   
Sex           
  Male 0.019  0.031 0.126  <.0001 
  Female Ref.   Ref.   
Insurance Type         
  Health Insurance -0.134  <.0001 0.203  <.0001 
  Medical Aids Ref.   Ref.   
Death After Diagnosis         
  Within a year 0.469  <.0001 -0.076  <.0001 
  During 1-1.99 yrs 0.026  0.053 0.280  <.0001 
  During 2-2.99 yrs -0.133  <.0001 0.160  <.0001 
  During 3-3.99 yrs -0.193  <.0001 0.107  <.0001 
  During 4-4.99 yrs -0.256  <.0001 -0.096  0.004 
  5 yrs Survivors Ref.   Ref.   
Diagnosed Year           
  2005 -0.112  <.0001 -0.049  <.0001 
  2006 -0.029  0.002 0.006  0.637 
  2007 Ref.   Ref.   
Home-Oxygen Therapy         
  User -0.0060  0.824 0.105  0.001 
  Non-User Ref.   Ref.   
Respiratory Disability         
  Disabled -0.207  <.0001 0.087  0.114 
  Non-disabled Ref.   Ref.   
            
ICU Days 0.022  <.0001 -0.002  0.086 
Ventilator Days -0.005  <.0001 0.000  0.935 
Number of Inpatient admissions 0.050  <.0001 0.033  <.0001 
            
Teaching Status         
  Teaching 0.129  0.001 0.158  <.0001 
  Non-Teaching Ref.   Ref.   
Hospital Type         
  Tertiary  -0.054  0.411 0.075  0.286 
  Large  -0.085  0.025 0.060  0.197 
  Small Ref.   Ref.   
          
# of 100 Beds 0.027  0.008 -0.014  0.213 
Nurses per 100 beds -0.002  0.902 0.012  0.359 


















Age Group             
  80- -0.213 0.124 -0.214 0.091 -0.107 0.694 
  70-79 0.111 0.419 0.076 0.546 0.417 0.124 
  60-69 0.375 0.007 0.291 0.021 0.844 0.002 
  50-59 0.472 0.001 0.340 0.007 1.008 <.0001 
  40-49 0.391 0.005 0.244 0.054 0.949 0.001 
  30-39 0.307 0.031 0.171 0.188 1.055 0.000 
  20-29 0.154 0.341 0.042 0.775 0.550 0.080 






Sex   
      
  Male 0.087 <.0001 0.088 <.0001 0.156 <.0001 







      
  Health Insurance 0.102 <.0001 -0.012 0.408 0.404 <.0001 






Death After Diagnosis 
      
  Within a year 0.538 <.0001 0.398 <.0001 -0.187 <.0001 
  During 1-1.99 yrs 0.490 <.0001 0.192 <.0001 0.819 <.0001 
  During 2-2.99 yrs 0.081 <.0001 -0.143 <.0001 0.515 <.0001 
  During 3-3.99 yrs -0.095 <.0001 -0.262 <.0001 0.348 <.0001 
  During 4-4.99 yrs -0.413 <.0001 -0.360 <.0001 -0.082 0.102 






Diagnosed Year   
      
  2005 -0.255 <.0001 -0.196 <.0001 -0.279 <.0001 
  2006 -0.115 <.0001 -0.088 <.0001 -0.074 <.0001 







      
  User 0.074 0.011 0.007 0.776 0.219 <.0001 







      
  Disabled 0.058 0.227 -0.089 0.043 0.271 0.001 






    
      
ICU Days 0.029 <.0001 0.030 <.0001 -0.003 0.054 
Ventilator Days -0.004 <.0001 -0.002 0.020 0.002 0.388 
Number of Inpatient admissions 0.070 <.0001 0.068 <.0001 0.058 <.0001 
    
      
Teaching Status 
      
  Teaching 0.375 <.0001 0.343 <.0001 0.315 <.0001 







      
  Tertiary  0.297 <.0001 0.339 <.0001 0.123 0.300 
  Large  0.105 0.019 0.127 0.002 -0.011 0.879 







      
# of 100 Beds 0.012 0.380 0.023 0.051 -0.001 0.945 
Nurses per 100 beds 0.038 0.031 0.019 0.213 0.052 0.022 




D-4-2. Healthcare utilization during first 12 months after lung cancer diagnosis 
    
Log of  
Inpatient LOS 
P 
Log of  
Outpatient Days 
P 
Age Group         
  80- -0.142  0.274 -0.016  0.930 
  70-79 0.086  0.509 0.218  0.243 
  60-69 0.185  0.153 0.446  0.017 
  50-59 0.211  0.105 0.513  0.006 
  40-49 0.111  0.396 0.428  0.022 
  30-39 0.008  0.953 0.454  0.018 
  20-29 -0.098  0.517 0.205  0.342 
  -19 Ref.   Ref.   
Sex           
  Male 0.015  0.101 0.119  <.0001 
  Female Ref.   Ref.   
Insurance Type         
  Health Insurance -0.152  <.0001 0.235  <.0001 
  Medical Aids Ref.   Ref.   
Death After Diagnosis         
  Within a year 0.604  <.0001 -0.322  <.0001 
  During 1-1.99 yrs 0.314  <.0001 0.478  <.0001 
  During 2-2.99 yrs -0.104  <.0001 0.268  <.0001 
  During 3-3.99 yrs -0.218  <.0001 0.144  <.0001 
  During 4-4.99 yrs -0.339  <.0001 -0.097  0.005 
  5 yrs Survivors Ref.   Ref.   
Diagnosed Year           
  2005 -0.112  <.0001 -0.033  0.008 
  2006 -0.025  0.008 0.017  0.153 
  2007 Ref.   Ref.   
Home-Oxygen Therapy         
  User 0.0253  0.348 0.159  <.0001 
  Non-User Ref.   Ref.   
Respiratory Disability         
  Disabled -0.207  <.0001 0.038  0.502 
  Non-disabled Ref.   Ref.   
            
ICU Days 0.023  <.0001 -0.002  0.205 
Ventilator Days -0.005  <.0001 -0.001  0.417 
Number of Inpatient admissions 0.066  <.0001 0.040  <.0001 
            
Teaching Status         
  Teaching 0.143  <.0001 0.325  <.0001 
  Non-Teaching Ref.   Ref.   
Hospital Type         
  Tertiary  -0.038  0.548 0.069  0.331 
  Large  -0.088  0.018 0.041  0.387 
  Small Ref.   Ref.   
          
# of 100 Beds 0.029  0.004 -0.021  <.0001 
Nurses per 100 beds -0.001  0.924 0.010  <.0001 







2002-2012년 국민건강보험 청구자료를 이용한 




서 론: 국내 폐암환자의 수는 지난 수십년간 꾸준히 증가하고 있으며, 폐암
은 암 관련 사망자 중 가장 큰 비중을 차지하고 있다. 또한 폐암환자로 인
한 의료비 및 의료이용 또한 증가하고 있는 추세이다. 국내의 폐암의 발병, 
유병, 사망등과 관련된 연구는 비교적 활발하게 이루진 반면 폐암환자의 
의료비 및 의료이용과 관련하여 전체기간별, 추적완료 전 기간, 폐암 진단
후 기간 등 다면적 분석을 시행한 연구는 부족한 현실이다. 또한 의료비와 
의료이용의 차이를 설명 할 수 있는 개인 및 병원 요인에 대한 국내 연구 
또한 부족한 현실이다. 따라서, 이 연구의 목적은 환자, 병원의 요인이 폐
암환자의 의료비 및 의료이용에 미치는 영향을 파악하는 것이다. 
 
자료 및 방법: 이 연구는 2002 년부터 2012 년까지의 전국민 폐암환자 국민
건강보험 청구자료를 바탕으로 이루어졌다. 해당기간 동안 총 1,417,380 건
의 청구건수가 있었으며, 그 중 673,122 건의 입원청구와 744,258 건의 외
래건수가 발생하였다. 해당자료를 바탕으로 이 연구는 청구자료를 환자 개
인단위의 후향성 코호트 디자인으로 전환하였다. 새로운 폐암 진단 환자의 
포함과 환자선택의 오류를 줄이기 위하여 2005 년 이후의 진단된 환자, 5
년 관찰추적을 마친 환자, 입원진료비 40 만원 이상 사용 환자를 대상으로 
하였다. 해당자료를 바탕으로 다양한 의료비 및 의료이용에 대한 측정을 
하였다 (전체의료비, 입원/외래 의료비, 추적완료 전 3,6,12 개월, 진단 후 
3,6,12 개월 등). 새롭게 생성된 데이터를 바탕으로 각 환자의 생존기간 또
한 측정하였다. 최종 데이터는 5 년 관찰 추적한 53,451 명의 폐암환자에 
대한 자료를 수집 및 분석을 하였으며 이에 상응하는 916 개 병원의 자료
를 매칭하였다. 전국민 폐암환자의 생존분석을 위하여 콕스비례위험모형 
(Cox-proportional hazard model)을 사용하였고, 폐암환자의 의료비 및 의료
이용에 영향을 미치는 환자 및 병원을 파악하기 위하여 선형혼합모형 




결 과: 2002 년에서 2012 년 전국민 건강보험 청구자료를 바탕으로 5 년 추
적환자, 후향성 코호트 디자인 연구의 분석결과, 해당기간 중 국가 단위 
폐암환자의 증가 (2005 년 16,654 명, 2006 년 18,149 명, 2007 년 18,648 명), 
의료비 및 의료이용의 증가가 있었으며 (전체의료비 22,883,645 원
~27,462,222 원; 입원재원일수 51.4 일~58.8 일; 외래이용일수 25.4 일~26.1 일), 
추적기간 종료 전, 진단 후 짧은 기간동안 많은 의료비 및 의료이용이 있
었음을 확인하였다 (전체 대비 70% 수준의 의료비 및 의료이용, 1 년 기준). 
콕스비례위험모형을 바탕으로 한 생존분석 결과 보험형태에 따른 위험비의 
차이는 확인 할 수 없었으나 (HR=0.99, P=0.489), 남자 (여자 vs. 남자, 
HR=0.74, P<0.001), 40 세 이상 연령이 높은 군에서의 위험비가 높은 것은 
확인 할 수 있었다 (HR 2.02~6.63, P<0.001). 선형혼합모형을 바탕으로 한 
폐암환자의 의료비 및 의료이용에 미치는 환자 및 병원의 요인을 분석한 
결과, 건강보험(전체 의료비 2.9% 증가, P<0.001; 외래이용 23.8% 증가, 
P<0.001), 남자(전체 의료비 5.6% 증가, P<0.001; 외래이용 8.6% 증가, 
P<0.001), 40-79 세 연령군 (전체 의료비 28.0%~61.0% 증가, P<0.001; 입원일
수 24.8% to 34.0% 증가, P<0.001; 외래이용 38.9%~65.8%, P<0.001) 및 상급
종합 및 종합병원 (전체 의료비 27.6%, 12.7% 증가, 수련병원 (전체 의료비
35.6% 증가, P<0.001; 입원일수 13.4% 증가, P=0.001; 외래이용 21.9% 증가, 
P<0.001) 에서의 의료자원 이용의 차이를 확인 할 수 있었다. 일부 인구집
단에서는 의료비 및 의료이용과 생존기간의 반비례 현상도 확인 할 수 있
었다.  
 
고찰 및 결론: 이 연구는 개인 수준의 건강보험 청구자료 및 병원 특성 자
료를 바탕으로 전 국민 폐암환자의 의료비 및 의료이용의 추세와 이에 영
향을 미치는 요인을 파악하였다. 이 연구의 결과는 국가 의료체계의 장기
적인 성과제고 및 효율적 보험재정 관리를 위한 정책 수립의 근거 자료를 
제시 하였다. 또한 이 연구는 폐암환자의 의료비 및 의료이용은 생존기간
을 고려하였으며, 일부 의료자원 이용의 차이가 확인된 인구집단에 대한 
관리의 필요성을 제기하고 있다. 마지막으로 이 연구의 결과는 비단 대한
민국뿐 아니라 의료자원 이용의 차이의 극복과 효율적 의료자원 지원을 포
괄하는 국가암관리사업 및 전략이 필요한 기타 국가에게 정책수립의 근거




핵심어: 폐암, 의료비, 의료이용, 생존기간 
